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Abstract
The development of high throughput sequencing (HTS) was followed by a swarm of
protocols utilizing HTS to measure different molecular aspects such as gene expression
(transcriptome), DNA methylation (methylome) and more. This opened opportunities
for developments of data analysis algorithms and procedures that consider data pro-
duced by different experiments.
Considering data from seemingly unrelated experiments is particularly beneficial
for Single cell RNA sequencing (scRNA-seq). scRNA-seq produces particularly noisy
data, due to loss of nucleic acids when handling the small amounts in single cells,
and various technical biases. To address these challenges, I developed a method called
netSmooth, which de-noises and imputes scRNA-seq data by applying network diffu-
sion over a gene network which encodes expectations of co-expression patterns. The
gene network is constructed from other experimental data. Using a gene network con-
structed from protein-protein interactions, I show that netSmooth outperforms other
state-of-the-art scRNA-seq imputation methods at the identification of blood cell types
in hematopoiesis, as well as elucidation of time series data in an embryonic develop-
ment dataset, and identification of tumor of origin for scRNA-seq of glioblastomas.
netSmooth has a free parameter, the diffusion distance, which I show can be selected us-
ing data-driven metrics. Thus, netSmooth may be used even in cases when the diffusion
distance cannot be optimized explicitly using ground-truth labels.
Another task which requires in-tandem analysis of data from different experiments
arises when different omics protocols are applied to the same biological samples. Ana-
lyzing such multi-omics data in an integrated fashion, rather than each data type (RNA-
seq, DNA-seq, etc.) on its own, is benefitial, as each omics experiment only elucidates
part of an integrated cellular system. The simultaneous analysis may reveal a compre-
hensive view. I developed a method called maui, to find latent factor representations of
multi-omics data. The method uses a variational autoencoder to learn nonlinear pat-
terns in different omics data types, and produces latent factor representations which
capture meaningful biology. I demonstrate its applicability on multi-omics data from
colorectal cancer (CRC) tumors and cancer cell lines. Latent factor representations pro-
duced by maui are predictive of patient survival, and they allow patients to be clus-
tered into molecular sub-types in a way which partly recreates the current gold-standard
for CRC sub-typing; moreover, I show that one of the current gold standard sub-types
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might need to be split into two groups of patients, with distinct survival probabilities
and dysregulation of different molecular pathways. I also used maui to quality-control
colorectal cancer cell lines; by quantifying the similarity of cancer cell lines to primary
tumors, i made predictions as to which cell lines are more appropriate models for the
different CRC sub-types.
Finally, application of netSmooth prior to feeding data to maui for multi-omics inte-
gration further improves the survival prediction capabilities of the method.
netSmooth is an R package and is obtainable from Bioconductor. maui is a python
package, and is available from PyPI.
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Zusammenfassung
Auf die Entwicklung der Hochdurchsatz-Sequenzierung (HTS) folgte eine Reihe von
speziellen Erweiterungen, die erlauben verschiedener zellbiologischer Aspekte wie Gen-
expression, DNA-Methylierung, etc. zu messen. Die Analyse dieser Daten erfordert die
Entwicklung von Algorithmen, die einzelne Experimenteberücksichtigen oder mehrere
Datenquellen gleichzeitig in betracht nehmen.
Der letztere Ansatz bietet besondere Vorteile bei Analyse von einzelligen RNA Se-
quenzierung (scRNA-seq) Experimenten welche von besonders hohem technischen
Rauschen, etwa durch den Verlust an Molekülen durch die Behandlung geringer Aus-
gangsmengen, gekennzeichnet sind. Um diese experimentellen Defizite auszugleichen,
habe ich eine Methode namens netSmooth entwickelt, welche die scRNA-seq-Daten en-
trascht und fehlende Werte mittels Netzwerkdiffusion über ein Gennetzwerk imputiert.
Das Gennetzwerk reflektiert dabei erwartete Koexpressionsmuster von Genen. Unter
Verwendung eines Gennetzwerks, das aus Protein-Protein-Interaktionen aufgebaut ist,
zeige ich, dass netSmooth anderen hochmodernen scRNA-Seq-Imputationsmethoden bei
der Identifizierung von Blutzelltypen in der Hämatopoese, zur Aufklärung von Zeitrei-
hendaten unter Verwendung eines embryonalen Entwicklungsdatensatzes und für die
Identifizierung von Tumoren der Herkunft für scRNA-Seq von Glioblastomen über-
legen ist. netSmooth hat einen freien Parameter, die Diffusionsdistanz, welche durch
datengesteuerte Metriken optimiert werden kann. So kann netSmooth auch dann einge-
setzt werden, wenn der optimale Diffusionsabstand nicht explizit mit Hilfe von exter-
nen Referenzdaten optimiert werden kann.
Eine integrierte Analyse ist auch relevant wenn multi-omics Daten von mehrerer
Omics-Protokolle auf den gleichen biologischen Proben erhoben wurden. Hierbei erk-
lärt jeder einzelne dieser Datensätze nur einen Teil des zellulären Systems, während die
gemeinsame Analyse ein vollständigeres Bild ergibt. Ich entwickelte eine Methode na-
mens maui, um eine latente Faktordarstellungen von multi-omics Daten zu finden. Das
Verfahren verwendet einen Variational Autoencoder, der nichtlineare Muster in ver-
schiedenen Omics-Datentypen zu lernen die biologisch interpretierbar sind.
Ich demonstriere seine Anwendbarkeit auf multi-omics Daten von Darmkrebs-(CRC)-
Tumoren und Krebszelllinien. Die von maui produzierten latenten Faktor sind prädik-
tiv für das Patientenüberleben, und ermöglichen es, Patienten in molekulare Subtypen
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zu gruppieren, so dass sie teilweise den aktuellen Goldstandard für die CRC Subtyp-
isierung nachbilden. Ein CRC-Subtyp ließ sich in zwei Gruppen von Patienten aufteilen,
welche durch unterschiedliche Überlebenswahrscheinlichkeiten und Dysregulation ver-
schiedener molekularer Pfade gekennzeichnet sind sind. Ich habe auch maui zur Qual-
itätskontrolle von Darmkrebs-Zelllinien verwendet, um festzustellen, welche Zelllinien
auf Grund ihrer Ähnlichkeit mit CRC-Subtypen am besten als Modelle für Drug Dis-
covery Studien geeignet sind.
Die Vorverarbeitung der Daten durch netSmooth und anschließende Verwendung von
maui verbessert die Vorhersage der Überlebenswahrscheinlichkeit. netSmooth ist ein R-
Paket und kann bei Bioconductor bezogen werden. maui ist ein Python-Paket und ist
über PyPI erhältlich.
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1
Introduction
Since the discovery of the structure of DNA and the birth of the field of molecular
biology that followed, new discoveries and experimental techniques have made biology
research astonishingly high tech. Especially since the completion of the Human Genome
Project nearly two decades ago, the proliferation of high throughput sequencing and a
plethora of experimental protocols have lead to a renaissance in the life sciences. The na-
ture of the molecular systems under study and the technologies employed have resulted in
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troves of experimental data which, while undeniably informative, is also rife with bias and
high variance. These developments have come in tandem with the development of compu-
tational biology, as statistical methods have been neccesitated by both the volume and other
challenges with the data.
A common theme throughout the developments of computational methods has been
to share information across different observations to tease out the patterns in spite of noise
and technical bias. Soon after practical DNA sequencing was invented (Sanger et al., 1977;
Maxam and Gilbert, 1977) in ground-breaking work that won Frederick Sanger his second
nobel prize in chemistry*, computational tools were taken advantage of. Sanger sequenc-
ing is only effective for fragments of limited length, but biologists soon set their sights on
sequencing whole genomes. By sequencing many small, randomly sheared, overlapping
DNA fragments, in a process termed shotgun sequencing, longer sequences may be assem-
bled by aligning fragment sequences based on their overlapping segments. The potential of
algorithms was realized quickly therafter (Staden, 1979), when they were used for de-novo
sequence assembly of bacteriophage genomes. Together with Sanger sequencing, shotgun
sequencing genome assembly algorithms (Batzoglou et al., 2002) formed the basis for the
Human Genome Project (HGP). The reference human genome eventually produced by
the HGP (International Human Genome Sequencing Consortium et al., 2004) represents a
consensus sequence of DNA donated by many volunteers from a diverse population†. This
makes the human reference genome itself the result of combining data frommany differ-
ent sequencing experiments. These developments set the stage for the now flourishing field
of computational biology, where philosophically similar problems and solutions are com-
mon: sharing information across experiments, considering uncertainty and, where possible,
*His first was for his work on protein sequence.
†In order to protect their privacy, many more donors were recruited whose samples were never se-
quenced.
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correcting errors.
As Sanger sequencing was replaced by Next Generation Sequencing (NGS) (Ronaghi
et al., 1996; Margulies et al., 2005), a wealth of sequencing protocols have been developed,
allowing researchers to probe molecular aspects other than the DNA sequence, e.g. gene
expression or DNAmethylation, using the same technology. Each such protocol came with
corresponding developments in bioinformatics, and often following the theme where an
algorithm attempts to reconstruct the forest from the trees, i.e. infer the bigger picture by
combining many noisy observations into a coherent story.
Prominent examples of this class of algorithm are frequently used in analyzing RNA
sequencing, ChIP sequencing, and Bisulfite sequencing (all described in more detail in Sec-
tion 1.2 on page 7). In RNA sequencing (RNA-seq) experiments, the goal is often to de-
termine differential gene expression under different conditions, e.g. a mutant vs. the wild
type, or a treated group vs. a control group (Oshlack et al., 2010). The noisy nature of both
biological systems and RNA-seq experiments means there will inevitably be some variance
in expression patterns between equally treated samples. In order to quantify differential
expression in the presense of such noise, statistical methods are employed, which learn pat-
terns across technical and biological replicates of the same conditions. By sharing parame-
ters in statistical distributions among e.g. different genes or different samples, the variance
of the different estimates can be reduced, and biological and technical variability can better
be quantified. Chromatin Immunoprecipiation (ChIP) sequencing can be used to profile
epigenetic states such as histone modifications (Barski et al., 2007). When different chro-
matin marks are examined together, they may be used to define genome-wide chromatin
states (Mikkelsen et al., 2007), i.e. active or silent chromatin domains, which can be inferred
from the makeup of different histone modifications. The different histone modifications
can be read in separate ChIPs, and algorithms (Ernst and Kellis, 2012) are used to statisti-
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cally infer the chromatin state of the element of interest (promoters, enhancers, etc). In fact,
most functional genomic elements, such as genes, promoters, and enhancers themselves
were discovered by integrating data frommany experiments and predicting the presence
of such elements algorithmically, such as was done throughout the ENCODE project (EN-
CODE Project Consortium et al., 2004, 2007). This is a prime example of combining data
from different sequencing experiments of the same (or similar) samples, leading to insights
which would not be possible otherwise. Other epigenetic assays such as Bisulfite sequenc-
ing or ATAC sequencing (also described in more detail in Section 1.2 on the next page) may
also be used to enrich the picture of the epigenetic landscape, and improve inferences, when
data from a multitude of experiments is combined.
In my doctoral studies, I have continued this very tradition. In the pages that follow, I
will describe two computational methods I have developed as part of my doctoral work.
The first is a method to reduce bias and variance in whole genome assays, using informative
priors about genes’ interaction patterns, which are learned from thousands of previous
experiments. The second method is a way to integrate multi-omics data, utilizing nonlinear
patterns within and across different data modalities and finding succinct representations
of the data which empower downstream analysis. I show the applicability of the methods
in analyzing single cell RNA sequencing, cancer subtyping, and quality control of cancer
models such as cell lines. I also show that using the two methods in tandem, integrating
data from both previous experiments and multi-omics experiments, results in improved
clinical relevance of cancer subtypes. Taken together, this dissertation makes up a body of
work which makes a modest contribution to the field.
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1.1 Thesis outline
In the following sections, I will introduce common genomic assays and data types
generated by those assays. Then I will introduce in more detail two problem areas where I
have made contributions. Section 1.3 on page 12 will introduce Single Cell RNA sequenc-
ing (scRNA-seq) and the drop-out problem, and in section 1.4 on page 16 I will present a
review of computational methods for multi-omics data integration, with a focus on ma-
trix factorization methods. The content is largely reproduced from (Akalin, Franke, Uyar,
and Ronen, 2019), where I authored the chapter on multi-omics data integration. It has
been edited for the overall clarity of this dissertation. Chapter 2 describes a novel method
for dealing with drop-outs in scRNA-seq by integrating data frommultiple experiments.
The method was published in (Ronen and Akalin, 2018a), from which the content is repro-
duced, with some editing for clarity in the context of this dissertation. Then, in chapter 3, I
present another method I developed, a deep learning-based latent vaiable model for multi-
omics data integration, with applications to cancer sub-typing. The content is reproduced
from (Ronen, Hayat, and Akalin, 2018). Finally, I discuss the overall impact of the work
and share some concluding remarks in chapter 4.
1.2 Genomic assays and data types
The postfix ome in molecular biology, such as in genome, implies a completeness of some
class. For instance, a transcriptome covers all the RNA transcripts in a biological sample,
and the proteome describes the totality of proteins. Hence, omics refers to comprehensive,
or total assays, where an entire class of something is characterized; e.g. transcriptomics refers
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to the characterization of the RNA transcripts in a sample, metabolomics to the profiling of
metabolites, etc.
In this section, I will briefly introduce some of the most common genomic assays and the
data types they produce.
DNA sequencing is a way to determine the sequence of nucleotides in DNA. First in-
vented in the 1970s and having inspired the world in the 1990s and early 2000s through
the Human Genome Project (HGP), today DNA sequencing is an indispensible part
of modern research in biology. Of the so-called second generation sequencing, which
was developed in the 1990s as a result of the HGP, the most commonly used today
is sequencing by synthesis. First, long DNAmolecules are cut into shorter fragments
using transposase. Then, adapters are ligated at the cut sites, which enable the frag-
ments to hybridize with oligonucleotides in the sequencing flow cell, holding them
in place. The fragments are then denatured, so that the forward and reverse strands
separate, and polymerases are used to make many copies of each strand (amplifica-
tion). Finally, primers are added to the DNA fragments which enable polymerases
to add special fluorescent tagged nucleotides with a terminator which enables the
process to be controlled and only happen one nucleotide at a time. Each of the four
possible bases is given a unique fluorescent color, and the sequence can be read by
observing the color at each cycle. This is done for many different molecules in par-
allel, enabling high throughput sequencing of an entire genome in hours (whole
genome sequencing, WGS). Sometimes, as a cost saving measure, only the coding
sequence of the genome is sequenced; this is referred to as whole exome sequencing
(WES). Once the genomic sequence of a sample is determined, we can compare it to
a reference sequence, and thus determine the presence or absence of single nucleotide
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polymorphisms (SNPs), insertions, deletions, and larger structural variations such
as copy number variations (CNV) or translocations. When used in this way to assert
the presence of mutations in a disease sample, bothWGS andWES data may be rep-
resented as a list of events (SNPs, insertions, deletions) and their coordinates, or, as is
done later in this text for analysis purposes, the mutation data may be represented as
anNgenes ×Nsamples binary matrix, wheremij = 1 iff. sample j has a deleterious mu-
tation in gene i, andmij = 0 otherwise. CNVs may be determined in e.g. a tumor by
comparing the read depth of a tumor sample to that of a normal (non-tumor) sam-
ple. In this way, deletions and amplifications may be discovered. The genome may
then be divided into segments which are deleted or amplified. Later in the text, I rep-
resent such data as anNsegments × Nsamples matrixC where cij is the copy number of
segment i in sample j.
ChIP sequencing or chromatin immunoprecipitation followed by sequencing (ChIP-seq),
is the use of NGS to study protein-DNA interactions in the nucleus. Chromatin im-
munopercipitation has been used to study such interactions since 1988 (Solomon
et al., 1988). It was later used in combination with hybridizaiton microarrays, in a
technique called ChIP-chip, and was first used in tandem with NGS in 2007 (John-
son et al., 2007; Barski et al., 2007; Robertson et al., 2007; Mikkelsen et al., 2007). In
ChIP, DNA and its bound proteins are cross-linked. Then the DNA-protein com-
plexes are sheared, and protein-specific antibodies are used to select the DNA frag-
ments associated with the protein of interest. The DNA fragments are sequenced
and aligned to a reference genome, which enables genome-wide mapping of a pro-
tein’s activity on the genome at base pair resolution. In spite of the presence of arti-
facts, ChIP-seq is the gold standard for mapping genome-wide protein-DNA interac-
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tions (Wreczycka et al., 2019). The data can be represented as a signal across genomic
coordinates, where each base is associated with a binding strength real-valued signal (a
normalized count of the reads covering that location).
Bisulfite sequencing refers to DNA sequencing preceded by bisulfite treatment of the
DNA, a reaction which converts cytosine residues to uracil, unless those cytosines are
methylated (Frommer et al., 1992). When the resulting sequence is compared with a
reference, an overview of the DNAmethylation (methylome), an important epige-
netic mark, may be inferred. Bisulfite-treated DNA sequencing (BS-seq) is the gold
standard for probing DNAmethylation (the methylome) genome-wide (Wreczycka
et al., 2017). The methylome is typically characterized by picking CpG’s (cytosines
followed by guanines) in the genome and measuring how often they are methylated.
This is called a beta value. The data can then be represented as anNCpGs × Nsamples
matrixC where cij is the beta value of CpG i in sample j.
RNA sequencing is used in the study and quantification of all RNA transcripts in a sam-
ple. Prior to the development of NGS, hybridization arrays were used to measure
gene expression, or the relative abundance of different mRNA transcripts in cells (De-
Risi et al., 1996). NGS was first used to quantify gene expression by sequencing
reverse-transcribed cDNA in 2008 (Morin et al., 2008). Today RNA sequencing
(RNA-seq) has all but replaced microarrays for gene expression quantification, thanks
to numerous advantages: it is less susceptible to cross-hybridization mistakes, it
has a better dynamic range, offering better detection of highly and lowly expressed
genes, and importantly, it does not require the transcript sequence to be known a-
priori (Grabherr et al., 2011), and can also be used to identify genetic variants. Using
reproducible data analysis pipelines (Wurmus et al., 2018), RNA-seq also provides
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superior fidelity than microarrays (Zhao et al., 2014). RNA-seq is performed by se-
quencing cDNA reverse-transcribed from RNA extracted from a sample. The reads
from the sequencing experiment are then aligned to a reference sequence, and each
is assigned to the gene (or transcript) it is thought to have originated from. The fi-
nal product is a read count for each transcript. This is typically characterized as an
Ntranscripts × Nsamples matrixE, where eij is some normalized gene expression value for
transcript i in sample j, which is derived from the read count, typically by normaliz-
ing to the library size (number of reads in the sample), the variability of the transcript
across samples, and transformed (using the 2-logarithm) so that it follows a normal
distribution.
ATAC sequencing (Assay for Transposase Accessible Chromatin) is an assay to determine
chromatin accessibility in a sample (Buenrostro et al., 2013). It is performed by first
treating DNAwith a special transposase which cuts loose accessible chunks of DNA
and ligates primers to them. Then, the resulting DNA fragments with primers are
amplified and sequenced. When mapped to a reference genome, these show which
parts of the genome are accessible, as there will be no reads from compacted chro-
matin. The accessibility of a genomic segment containing genes is a requirement
for polymerase to be able to transcribe any genes from that segment, and so chro-
matin accessibility is an important epigenetic mark. ATAC sequencing reads which
are mapped to the genome may be segmented into ”peaks” (segments with many
mapped reads), and the data may be represented as anNpeaks × Nsamples matrix T ,
where tij is the normalized magnitude of peak i in sample j. These may also be bina-
rized, i.e. tij ∈ {0, 1}.
Other common omics assays which will not be covered in much detail in this disserta-
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tion include proteomics and metabolomics, the characterization of the proteins or
the profiling of metabolites, respectively. While different techniques exist for both
purposes, both proteomics and metabolomics is typically performed using mass
spectrometry, thanks to the ability to profile hundreds of thousands of kinds of
molecules in parallel, as with high throughput sequencing.
1.3 Single cell RNA sequencing:
challenges with single cell transcriptomics
Soon after NGSwas applied to bulk transcriptome profiling, it was also used suc-
cessfully on mRNA extracted from single cells (Tang et al., 2009). Single cell gene expres-
sion was done using qPCR (Eberwine et al., 1992) and single-molecule FISH (Tyagi and
Kramer, 1996) over a decade earlier. Full-scale transcriptomics using microarrays was first
demonstrated in 2003 (Tietjen et al., 2003). However, it was later developments in barcod-
ing and multiplexing (Islam et al., 2011) followed by the use of microfluidics (Klein et al.,
2015; Macosko et al., 2015) which really necessitated new computational techniques for
single cell RNA sequencing (scRNA-seq). Barcodes, multiplexing, and microfluidics have
made it possible to sequence millions of single cells. At the time of writing, the largest study
known to me has sequenced the transcriptomes of 1.3 million single cells (10x Genomics,
2017), and the Human Cell Atlas (Regev et al., 2018) has its sights set on all the cells. How-
ever the small amount of mRNAwhich can be extracted from a single cell, along with the
stochastic nature of transcription, makes scRNA-seq analysis distinct from bulk RNA-seq.
After reads from scRNA-seq are mapped to a reference transcriptome, normalization strate-
gies from bulk RNA-seq turned out to be inadequate, as they assume a constant amount
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of mRNA per sample, and single cells from different populations can have varying sizes,
and hence mRNA content. Normalization, clustering, and differential expression analyses
are all affected by the difference in mRNA content between cell populations in ways that
bulk RNA-seq experiments are not (reviewed in Bacher and Kendziorski (2016)). In addi-
tion, novel analyses have been devised which also take advantage of measurements of other
cells when inferring something about a single cell’s state. One such ground-breaking tech-
nique is pseudo-temporal ordering of single cells (Trapnell et al., 2014), which has enabled
the study of e.g. cell differentiation trajectories in the transcriptome, while taking fewer
temporal time points than would otherwise be neccesary. Studies ranging from cell type
identification and discvery, to cell differentiation, cell cycles, and tumor heterogeneity have
all benefited greatly from the continued improvements in the number of single cells which
may be sequenced and the depth at which they may be sequenced. Whether single cells are
manually picked with surgical precision pipetting, or whether sophisticated microfluidics
platforms are used to prep hundreds of thousands of single cells, in principle any of the
assays described above can be performed on single cells, with the caveat that some of the an-
alytes extracted from single cells (DNA, RNA, proteins) is liable to be lost in the process.
Hence, single cell omics stands as an exciting application for all of the above mentioned
technologies.
The most common single cell assay at this time is single cell RNA sequencing. A major
difficulty with single cell RNA sequencing arrises from the fact that up to 85% of the RNA
in a cell may be lost when handling it, due to the physical difficulty of handling such small
amounts. In addition, transcription dynamics may result in a cell containing no mRNA
transcripts of a gene which is active in that cell at that time in some other sense, e.g. the pro-
tein might still be found in the cell*. The resulting data exhibits even stronger bias and high
*In other words, mRNA counts from RNA-seq experiments are only a proxy for gene expression. More
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variance than bulk sequencing data, and in addition suffers from zero inflation (drop-outs)
which happens when a transcript isn’t detected in RNA sequencing although it was present
in a cell in some nonzero amount. Many common down-stream analyses for gene expres-
sion data are heavily impacted by missing values, and so computational biologists have
been imputing missing gene expression data since the days of microarrays (Troyanskaya
et al., 2001). Bulk RNA-seq does not suffer frommissing values as much as microarrays.
However, the drop-out problem in scRNA-seq has lead to a renewed interest in imputation
methods specific to scRNA-seq.
Data imputation for single cell RNA sequencing
While estimated transcript abundances in each single cell from a single cell RNA
sequencing experiment might only cover about 15% of the total RNA in the cell, microflu-
idics platforms have made experiments including tens of thousands of cells common. Un-
der the assumption that cells of the same cell type express roughly the same genes with sim-
ilar relative abundances, it is possible to attempt to impute, i.e. fill inn missing values for
genes with zero counts, by comparing each single cell to other single cells which are similar
to it. Two similar * cells of the same cell type might express a very similar mixture of genes
at a given time, but the stochastic transcription, extraction, amplification, and sequencing
process might lead to different genes being dropped out from each cell. When the observed
part of the two cells’ transciptomes are sufficiently similar, we might use them to impute
each other’s missing values (drop-out genes). Several algorithms have been published that
attempt this, with varying levels of sophistication:
on this in chapter 2
*Similar here means the observed part of the transcriptome is similar.
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Imputation using mean values The simplest way to impute a missing value is by the mean
among non-missing values, i.e. for each observed zero, we may fill in the mean among
the nonzero samples. This naïve approach has a major weakness in that it assumes
all genes are equally likely to be drop-outs, and thus fills in all zero values. A note-
worthy result about the drop-out rate of a gene, i.e. the proportion of cells which
have a 0 count of that gene, is that it is exponentially proportional to the mean ex-
pression level of that gene (Kharchenko et al., 2014a). Thus, once each gene’s mean
expression value (across samples) is calculated, each zero count may be filled in to the
mean expression among genes with a similar drop-out rate to the gene in question.
A weakness of this slightly less naïve method is that we expect mean expression of a
gene to vary across cell types, and so for experiments profiling more than a single cell
type (most single cell RNA sequencing experiments) this is a major weakness. This
weakness may be addressed by first clustering cells, and then performing this step
within each cluster separately. A representative of this class of imputation methods is
CIDR (Lin et al., 2017).
Model based imputation The next step in sophistication is trying to model genes’ drop-out
likelihood explicitly, as well as genes’ expression values as predicted by other genes’
expression values. A representative of this class of methods is scImpute (Li and Li,
2017). scImpute first estimates each gene’s drop-out likelihood by fitting a bi-modal
distribution to the global expression pattern, and assigning for each gene, in each cell,
a likelihood that the value is a drop-out as opposed to a true 0 expression. It then
uses linear models based on the genes which are predicted to not be drop-outs, to
regress the expression values of genes which are determined to be likely drop-outs.
Imputation using local neighborhoods Local neighborhood imputation is based on the
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assumption that, in spite of drop-outs, the gene expression profiles of single cells will
fall on a smooth manifold where nearby cells are likely to have similar true expression
patterns. MAGIC (van Dijk et al., 2017) is such a method, and it works by learning
such a manifold using network diffusion on a first-order similarity graph, followed
by local averaging i.e. squeezing of the expression profiles to lie exactly on the mani-
fold it predicts. It is the most aggressive of the imputation methods described in this
section, changing expression values of all genes in all samples to best explain the ob-
served neighborhoods.
In Chapter 2, I will describe a method I developed for dealing with missing or noisy val-
ues in scRNA-seq experiments, and which does not rely on similar cells from the same ex-
periment for the imputation, thus side-stepping the risk of amplifying inherent biases in a
single experiment.
1.4 Multi-omics data integration
ome and omics refer to comprehensive data types. Multi-omics in turn refers to data
spanning different genomics assays. When multiple omics platforms are used on the same
biological samples, the resulting multi-modal datasets allow us to probe biological processes
frommultiple aspects. This is referred to as multi-omics data integration, and is common
in the field of cancer research (Hoadley et al., 2014). Multi-omics experiments are also be-
coming more common in single cells (Dey et al., 2015). In this section, I will discuss some
multi-omics analysis strategies, with emphasis on latent variable models for multi-omics
integration, focusing, among these, on matrix factorization methods.
The contents of this section are largely reproduced from Computational Genomics with
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R, Altuna Akalin, Vedran Franke, Jonathan Ronen, Bora Uyar (in press), where I wrote
the corresponding chapter. It has been edited for clarity in this dissertation.
Multi-omics data analysis strategies
Like in many other data analytics and machine learning applications, multi-omics
data integration algorithms may be split into supervised and unsupervised methods. Un-
supervised multi-omics integration methods are methods that look for patterns within and
across data types, in a label-agnostic fashion, i.e. without knowledge of the identity or label
of the analyzed samples (e.g. cell type, tumor/normal). Supervised integration methods,
unlike the unsupervised variety, make use of available labels, such as phenotypes.
Beyond the supervised / unsupervised dichotomy, common strategies for multi-omics
data analysis can be further divided into three categories:
Sequential Analysis of multi-omics data includes methods such as CNAmet (Louhimo
and Hautaniemi, 2011), where gene expression data (RNA-seq) is used to find up- or
down-regulated genes, DNAmethylation data (BS-seq) is used to find hyper- and
hypo-methylated genes, and copy-number variation data (eg. fromDNA-seq) is used
to see if genes have gains or losses in DNA copy-number. By analyzing each data
type independently, CNAmet computes a score that estimates why genes are up-
or down-regulated in cancer; if it is because of aberrant DNAmethylation, gain or
loss of copy-number, or both. Thus, data from different genomic assays can be used
together to study gene expression regulation.
Network-based methods seek to leverage algorithms developed for graph data in order to
integrate multi-omics data. They broadly fall into two categories — one where the
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network is defined over genes, with edges denoting some kind of interaction or simi-
larity between them, and the other where the network is defined over samples, where
edges signify similarity among the samples. In the former (gene-network), the goal is
often to identify genes that are implicated in a process, often using the ”guilt through
association” method, where a gene network is constructed frommulti-omics data,
and genes are implicated in some underlying process if they are adjacent to other
genes which are related to that process. In the second appraoch (sample network),
one builds a graph over samples, where edges signify that samples are close, or sim-
ilar, in some omics data type. The graph may be trimmed so that only nodes with
edges in multiple omics data types retain their edges, and the resulting graph can be
used for graph-based analysis such as spectral clustering etc.
Matrix factorization methods have long been a workhorse of unsupervised learning due
to their scalability and applicability. The extension from single-data types to multi-
omics integration is straightforward. They will be discussed in more detail through-
out the rest of this section.
Latent variable models for multi-omics integration
Latent variable models are a dimensionality reduction technique. They make an as-
sumption that the high dimensional data we observe (e.g. counts of tens of thousands of
mRNAmolecules) arrise from a lower dimension description. The variables in that lower
dimensional description are termed latent variables, as they are believed to be latent in the
data, but not directly observable through experimentation. Therefore, there is a need for
methods to infer the latent variables from the data. For instance, the relative abundance of
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different mRNAmolecules in a cell might be largely determined by the cell type or state.
There are other experiments which may be used to discern the cell type (e.g. looking at cells
under a microscope), but an RNA-seq experiment does not, directly, reveal whether the an-
alyzed sample was taken from one organ or another. A latent variable model might set the
cell type as a latent variable, and the observable abundance of mRNAmolecules to be de-
pendent on the value of the latent variable (e.g. if the latent variable is ”Regulatory T-cell”,
we would expect to find high expression of CD4, FOXP3, and CD25).
Matrix factorization for unsupervised multi-omics data integration
Matrix factorization techniques attempt to infer a set of latent variables from the
data by finding factors of a data matrix. Principal Component Analysis is a form of matrix
factorization which finds factors based on the covariance structure of the data. Generally,
matrix factorization methods may be formulated as
X = WH,
whereX is theNfeatures ×Nsamples data matrix,W is anNfeatures ×Nlatent factors feature weight
matrix, andH is theNlatent factors × Nsamples latent variable coefficient matrix. ThisH is
the reduced dimension representation. Tying this back to PCA, whereX = UΣV T , we
may formulate the factorization in the same terms by settingW = UΣ andH = V T . If
Nlatent factors = rank(X), this factorization is lossless, i.e. X = WH . However if we choose
Nlatent factors < rank(X), the factorization is lossy, i.e. X ≈ WH . In that case, matrix
factorization methods normally opt to minimize the error
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SamplesFeatures (genes)
Figure 1.1: General matrix factorization framework. The data matrix on the left hand side is decomposed into factors
on the right hand side. The equality may be an approximation as some matrix factorization methods are lossless
(exact), while others are an approximation. This figure is reproduced from Akalin et al. (2019).
min ‖X −WH‖,
which may be further subject to some constraints or regularization terms. As we nor-
mally seek a latent variable model with a considerably lower dimensionality thanX , this is
the more common case.
Figure 1.1 illustrates matrix factorization. There, the 5 × 4 data matrixX is decomposed
to a 2-dimensional latent variable model.
Multiple factor analysis (MFA) (Blasius, 2006) is a natural starting point for a discussion
about matrix factorization methods for intergrating multiple data types. It is a straight-
forward extension of PCA into the domain of multiple data types *.
Consider Figure 1.2 on the next page, a naïve extension of PCA to a multi-omics con-
*When dealing with categorical variables, MFA uses MCA (Multipe Correspondence Analysis). This is
less relevant to biological data analysis and will not be discussed here
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Figure 1.2: A naïve extension of PCA to multi-omics; data matrices from different platforms are stacked, before ap-
plying PCA. This figure is reproduced from Akalin et al. (2019).
text. Formally, we have
X =

X1
X2
...
XL

= WH,
a joint decomposition of the different data matrices (Xi) into the factor matrixW
and the latent variable matrixH . This way, we can leverage the ability of PCA to find
the highest variance decomposition of the data, when the data consists of different
omics types. As a reminder, PCA finds the linear combinations of the features which,
when the data is projected onto them, preserve the most variance of anyK dimen-
sional space. But because measurements from different experiments have different
scales, they will also have variance (and co-variance) at different scales.
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MFA addresses this issue and achieves balance among the data types by normalizing
each of the data types, before stacking them and passing them on to PCA. Formally,
MFA is given by
X˜ =

X1/λ
(1)
1
X2/λ
(2)
1
...
XL/λ
(L)
1

= WH,
whereXi are data matrices from different omics platforms, and λ
(i)
1 is the first eigen-
value of the principal component decomposition ofXi, i.e. MFA is equivalent to
performing PCA on a concatenated data matrix where each component data matrix
is normalized by its largest eigenvalue.
Joint Non-negative Matrix Factorization (Yang and Michailidis, 2015) NMF (Non-negative
Matrix Factorization) is an algorithm from 2000 that seeks to find a non-negative
additive decomposition for a non-negative data matrix. It takes the familiar form
X ≈ WH , but with the non-negativity constraintsX ≥ 0,W ≥ 0, andH ≥ 0.
The non-negative constraints make a lossless decomposition (i.e. X = WH) gener-
ally impossible. However, many data types are inherently non-negative; for instance,
transcript counts from RNA-seq experiments are non-negative, making negative
loadings in e.g. PCA undesirable for the purpose of biological interpretation. Hence,
NMF attempts to find a solution which minimizes the Frobenius norm of the recon-
struction:
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min ‖X −WH‖F
W ≥ 0,
H ≥ 0.
This is typically solved forW andH using random initializations followed by itera-
tions of a multiplicative update rule:
Wt+1 = W
T
t
XHTt
XHtHTt
(1.1)
Ht+1 = Ht
W Tt X
W Tt WtX
. (1.2)
Since this algorithm is guaranteed only to converge to a local minima, it is typically
run several times with random initializations, and the best result is kept.
In the multi-omics context, we will, as in the MFA case, wish to find a decomposition
for an integrated data matrix of the form
X =

X1
X2
...
XL

,
withXis denoting data from different geomic assays.
As NMF seeks to minimize the reconstruction error ‖X −WH‖F , some care needs
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to be taken with regards to data normalization. Different omics platforms may pro-
duce data with different scales (i.e. real-valued gene expression quantification, binary
mutation data, etc.), and so will have different baseline Frobenius norms. To address
this, when doing Joint NMF, we first feature-normalize each data matrix, and then
normalize by the Frobenius norm of the data matrix. Formally, we run NMF on
X˜ =

XN1 /α1
XN2 /α2
...
XNL /αL

,
whereXNi is the feature-normalized data matrixX
N
i =
xij∑
j x
ij , and αi = ‖XNi ‖F .
Another consideration with NMF is the non-negativity constraint. Different omics
data types may have negative values, for instance, copy-number variations (CNVs)
may be positive, indicating gains, or negative, indicating losses. In order to turn such
data into a non-negative form, we will split each feature into two features, one new
feature holding all the non-negative values of the original feature, and another fea-
ture holding the absolute value of the negative ones. By representing each segment
by two rows, one for losses and one for gains, we can represent CNV data as non-
negative.
iCluster (Shen et al., 2012) takes a Bayesian approach to the latent variable model. In Bayesian
statistics, we infer distributions over model parameters, rather than finding a maximum-
likelihood parameter estimates. In iCluster, we model the data as
X(i) = W(i)Z + i,
24
SamplesFeatures 1
Features 2
Features 3
Noise
Figure 1.3: Sketch of iCluster model. Each omics datatype is decomposed to a coefficient matrix and a shared latent
variable matrix, plus noise. This figure is reproduced from Akalin et al. (2019).
whereX(i) is a data matrix from a single genomic assay,W(i) are model parameters,
andZ is the latent variable matrix, which is shared between the different omics plat-
forms. i is a ”noise” random variable,  ∼ N(0,Ψ), whereΨ = diag(ψ1, . . . ψM)
is a diagonal covariance matrix. This is a way of formalizing uncertainty in the model
and allow for discrepancies.
With this formulation, the omics measurementsX are expected to be the same for
samples with the same latent variable representation, up to gaussian noise. Further,
we assume a Gaussian prior distribution on the latent variablesZ ∼ N(0, I), which
means we assumeX(i) ∼ N
(
0,W(i)W
T
(i) + Ψ(i)
)
. In order to find suitable values
forW ,Z , andΨ, we can write down the multivariate normal log-likelihood function
and optimize it. For a multivariate normal distribution with mean 0 and covariance
Σ, the log-likelihood function is given by
 = −1
2
(
ln(|Σ|) +XTΣ−1X + k ln(2pi)
)
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(this is simply the log of the Probability Density Function of a multivariate gaus-
sian). For the multi-omics iCluster case, we haveX =
(
X(1), . . . , X(L)
)T
,W =(
W(1), . . . ,W(L)
)T
, whereX is a multivariate normal with 0-mean andΣ = WW T+
Ψ covariance. Hence, the log-likelihood function for the iCluster modle is given by:
`iC(W,Σ) = −1
2
( L∑
i=1
ln(|Σ|) +XTΣ−1X + pi ln(2pi)
)
where pi is the number of features in omics data type i. Because this model has more
parameters than we typically have samples, we need to push the model to use fewer
parameters than it has at its disposal, by using regularization. iCluster uses Lasso
regularization, which is a direct penalty on the absolute value of the parameters. I.e.,
instead of optimizing `iC(W,Σ), we will optimize the regularized log-likelihood:
` = `iC(W,Σ)− λ‖W‖1.
The parameter λ acts as a dial to weigh the tradeoff between better model fit (higher
log-likelihood) and a sparser model, with morewijs set to 0, which gives models
which may generalize better and are more interpretable.
In order to solve this optimization problem, iCluster employs the ExpectationMaxi-
mization (EM) algorithm (Dempster et al., 1977), the full details of which are beyond
the scope of this text. I will introduce a short sketch instead. The intuition behind
the EM algorithm is a more general case of the k-means clustering algorithm.
EM algorithm sketch
• InitializeW andΨ
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• Until convergence ofW ,Ψ
– E-step: calculate the expected value ofZ given the current estimates ofW
andΨ and the dataX
– M-step: calculate maximum likelihood estimates for the parametersW
andΨ based on the current estimate ofZ and the dataX .
iCluster+ (Mo and Shen, 2013) is an extension of the iCluster framework, which allows for
omics types to arrise from other distributions than a gaussian. While normal distri-
butions are a good assumption for log-transformed, centered gene expression data, it
is a poor model for binary mutations data, or for copy number variation data, which
can typically take the values (−2, 1, 0, 1, 2) for heterozygous / monozygous dele-
tions or amplifications. iCluster+ allows the differentXs to have different distribu-
tions:
• For binary mutations,X is drawn from a multivariate binomial,
• for normal, continuous data,X is drawn from a multivariate gaussian,
• for copy number variations,X is drawn from a multinomial,
• for count data,X is drawn from a poisson.
In that way, iCluster+ allows us to explicitly model our assumptions about the dis-
tributions of our different omics data types, and leverage the strengths of Bayesian
inferrence.
Both iCluster and iCluster+ make use of sophisticated Bayesian inference algorithms
(EM for iCluster, Metropolis-Hastings MCMC for iCluster+), which means they do
not scale up trivially. Therefore, it is recommended to filter down the features to a
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manageable size before inputing data to the algorithm. The exact size of ”manage-
able” data depends on your hardware, but a rule of thumb is that dimensions in the
thousands are ok, but in the tens of thousands might be too slow.
Multi-Omics Factor Analysis (MOFA) (Argelaguet et al., 2018) is a latent factor multi-
omics integration method which solves the same problem definition as iCluster and
iCluster+ (Figure 1.3 on page 25). However, while iCluster solves the poblem using
the EM algorithm, and iCluster+ using MCMC,MOFA uses variational mean-field
approximation. A benchmark comparing MOFA to iCluster+, as well as tomaui, a
method I developed, is presented in Chapter 3.
Down-stream analysis for latent variable methods
The latent variable methods described above can only ever make up part of an inter-
esting analysis of multi-omics data. However, a latent factor representation of multi-modal
data facilitates down-stream analysis which would be difficult to do without first reducing
the dimensionality of the data. This section describes common analyses which are assisted
by latent factor methods.
Clustering using latent factors
A common analysis in biological investigations is clustering. This is often interesting
in cancer studies as one hopes to find groups of tumors (clusters) which behave similarly,
i.e. belong to the same risk group and/or respond to the same drugs. In single cell studies,
clustering is often used to define cell types. Additionally, clustering is often used in studies
which aim to find differences between e.g. gene expression of some treatment sample and
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a control, where clustering may be seen as a confirmatory step that shows treatment and
control groups are indeed discriminable in experimental data. PCA is a common step in
clustering analyses, and so it is easy to see how the latent variable models discussed above
may all be a useful pre-processing step before clustering.
One-hot clustering A specific clustering method which is used in tandem with NMF is to
assume each sample is driven by one component, i.e. that the number of clustersK
is the same as the number of latent variables in the model and that each sample may
be associated to one of those components. We assign each sample a cluster label based
on the latent variable which affects it the most.
The one-hot clustering method does not lend itself very well to the other methods
discussed above, i.e. iCluster andMFA. The latent variables produced by those other
methods may be negative, and further, in the case of iCluster, are going to assume a
multivariate gaussian shape. As such, it is not trivial to pick one ”dominant factor”
for them. For NMF variants however, this is a very common way to assign clusters.
K-means clustering is a special case of the EM algorithm, and indeed iCluster was origi-
nally motivated as an extension of K-means from binary cluster assignments to real-
valued latent variables. The iCluster algorithm, as it is so named, calls for application
of K-means clustering on its latent variables, after the inference step. K-means lends
itself well to clustering on latent factors which are normally distributed, as the main
assumption of K-means clustering is that each sample will be closer to the mean of its
cluster than to that of other clusters.
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Biological interpretation of latent factors
Latent factor representations are useful for down-stream analysis such as cluster-
ing, but biologists are rightfully averse of so-called black boxmodels, where the relationship
between what goes in (omics) and what comes out (latent factors) is opaque. Hence, it is
important that we are able to interpret the meaning of latent factors in the context of what
is known about the biology of the features (e.g. genes) they summarize.
Inspection of feature weights in loading vectors The most straightforward way to go
about interpreting the latent factors in a biological context, is to look at the coeffi-
cients which are associated with them. The latent variable models introduced above
all take the linear formX ≈ WH , whereW is a factor matrix, with coefficients tying
each latent variable with each of the features in the L original multi-omics data matri-
ces. By inspecting these coefficients, we can get a sense of which multi-omics features
are co-regulated.
Disentangled representations A desirable property of latent factor representations, one
which simplifies their interpretation and down-stream analysis, is for each input
feature to be prediminantly associated with a single latent factor. This property is
termed disentangledness, i.e., it leads to disentangled latent variable representations,
as changing one input feature only affects a single latent variable.
Enrichment analysis The recent decades of genomics have uncovered much about the
ways in which genes cooperate to perform biological functions in concert. This work
has resulted in rich annotations of genes, groups of genes, and the different functions
they carry out. Examples of such annotations include the Gene Ontology Consor-
tium’sGO terms (Ashburner et al., 2000; Consortium, 2017), the Reactome pathways
30
database (Fabregat et al., 2018), and theKyoto Encyclopaedia of Genes and Genomes
(Kanehisa et al., 2017). These resources, as well as others, publish lists of so-called
gene sets, or pathways, which are sets of genes which are known to operate together
in some biological function, e.g. protein synthesis, DNAmismatch repair, cellular
adhesion, and many,many other functions.
These gene sets are used to annotate genes of interest in particular studies. For in-
stance, by performing a differential expression analysis we migh uncover a set of
genes which are upregulated under some condition. By comparing these genes with
the published gene sets, we may find that similar genes are implicated in other biolog-
ical processes. This is termed gene set enrichment analysis, and is commonly used by
researchers to further their understanding of the systems they study.
In the context of making sense of latent factors, the question we will be asking is
whether the genes which drive the value of a latent factor (the genes with the high-
est factor coefficients) also belong to any interesting annotated gene sets, and whether
the overlap is greater than we would expect by chance. If there areN genes in total,
K of which belong to a gene set, the probability that k out of the n genes associated
with a latent factor are also associated with a gene set is given by the hypergeometric
distribution: P (k) =
(K
k
)−(N−K
n−k
)(N
n
) .
The hypergeometric test uses the hypergeometric distribution to assess the statistical
significance of the presence of genes belonging to a gene set in the latent factor. The
null hypothesis is that there is no relationship between genes in a gene set, and genes
in a latent factor. When testing for over-representation of gene set genes in a latent
factor, the P value from the hypergeometric test is the probability of getting k or
more genes from a gene set in a latent factor: p =
∑K
i=k P (k = i).
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The hypergeometric enrichment test is also referred to as Fisher’s one-sided exact test.
This way, we can determine if the genes associated with a factor significantly overlap
(beyond chance) the genes involved in a biological process. Because we will typically
be testing many gene sets, we will also need to apply multiple testing correction, such
as Benjamini-Hochberg correction.
The remainder of this thesis
In the chapters that follow, I will describe in depth two novel methods I have developed
as part of my doctoral studies. The first method, called netSmooth (Ronen and Akalin,
2018a), uses priors from earlier published data in order to temper noisy measurements in
scRNA-seq. In chapter 2, I will expand on ideas introduced on page 14, and introduce the
netSmoothmethod. I will show results comparing netSmooth to other state-of-the-art pre-
processing methods for scRNA-seq on different scRNA-seq datasets representing different
biological systems.
In chapter 3, I will describe a deep learning based method I developed calledmaui (Ro-
nen et al., 2018), which learns latent factor representations of multi-omics data using a
stacked variational autoencoder. While it is applicable to any multi-omics dataset, be it
from single cells or bulk, I will demonstrate its utility in sub-typing colorectal cancers us-
ing bulk multi-omics data from primary tumor biopsies. In the same chapter, I will also
show that netSmooth can be repurposed for pre-processing of data other than scRNA-seq,
and that using netSmooth together withmaui enables us to further improve the clinical rele-
vance of cancer sub-types.
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2
Imputing scRNA-seq with priors from
other experiments
Single cell RNA sequencing (scRNA-seq) is a powerful assay which allows researchers
to probe genome-wide expression patterns in millions of single cells. However, with mea-
surements from each single cell covering as little as 15% of its transcriptome, the utility of
such studies depends on computational data imputation methods. Imputation methods
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typically involve guessing an observed 0’s true value by looking at other cells which are sim-
ilar (see section 1.3.1 on page 14). While this approach has demonstrated utility in many
cases, it is not without issues. One issue is that single cell RNA sequencing experiments
also suffer from technical biases, e.g. different capture rates for different genes. In the pres-
ence of such inherent biases in the data from a single experiment, imputing using other
datapoints from the same experiment can amplify these technical biases, overshadowing the
true biological variability that experimenters are interested in. In this chapter, I describe a
different approach to data imputation - one which uses data from other experiments as a
template.
The contents of this chapter are adapted from Ronen and Akalin (2018a). Most sections
are reproduced verbatim, but have been rearranged and edited to fit this format.
2.1 Introduction
With unprecedented throughput and resolution, scRNA-seq has enabled
many studies which were previously impractical, such as characterization of cell type het-
erogeneity, differentiation, and developmental trajectories (Wagner et al., 2016). However,
the adaptation of RNA sequencing techniques from bulk samples to single cells did not
progress without challenges. Typically, only a fraction of a cell’s transcriptome is captured
by the experiment, leading to so called dropout events where a transcript is not observed in
some cell in spite of it being expressed there. RNA-seq experiments produce read counts
quantifying the abundance of different transcripts, or genes*, in a cell. When an expressed
gene is not captured in an RNA-seq experiment, the resulting count for that gene will be
zero; this is what is most commonly referred to as a dropout event. When a fraction of
*I will use transcripts and genes interchangeably throughout this section.
34
a gene’s mRNA is captured by an RNA-seq experiment, producing a read count which
is lower than the actual expression level (relative to other genes), it is also referred to as a
dropout. The dropout rate is related to the population level expression of a gene, leading
to many false zero counts for lowly expressed genes, and artificially low counts for highly
expressed ones (Kharchenko et al., 2014b). The dropout rate is also related to the biology
of the cell type, as some cell types transcribe fewer genes than do others, which may appear
intistinguishable from dropout events (Kharchenko et al., 2014b). To what extent dropouts
are a technical artifact, and howmuch they are caused by ”bursty” transcription, remains
an open question; but for a range of reasons, only some of which are understood, when
summed over many samples, transcript counts from single cells resemble those of bulk ex-
periments (Wu et al., 2014), while across individual cells there is significant variation. This
makes analysis more difficult than in bulk RNA sequencing experiments.
Computational methods designed to deal with these issues treat dropout events as miss-
ing data points, whose values are to be imputed based on non-missing data points (ob-
served measurements). The proportion of cells with zero counts per gene, a proxy for its
technical dropout rate, is a function of the population-wise mean expression of that gene
(Pierson and Yau, 2015; Kharchenko et al., 2014b). This observation has led researchers to
treat zero counts as dropout candidates to be imputed.
CIDR (Lin et al., 2017) attempts to impute missing values based on the predicted mean
expression of a gene, given its empirical dropout rate (zero count). scImpute (Li and Li,
2017) estimates dropout likelihoods per gene and per sample, and assigns each gene in each
sample a status as a dropout candidate. scImpute may consider genes to be likely dropouts
even with nonzero expression, and zero count genes might not be considered likely dropouts,
based on their population-wide expression distributions. scImpute then uses a regularized
linear model to predict the expression of dropout genes based on the expression of likely
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non-dropouts in all other cells. MAGIC (van Dijk et al., 2017) performs local averaging af-
ter building a topological graph of the data, updating the expression value of all genes in all
cells to their local neighborhood average.
The methods mentioned above use information present in the data in order to impute
the missing information within the same data. As such, they amplify whatever biases are
present in a dataset; similar cells pre-imputation will become more similar after imputation,
as expression profiles of non-dropout genes will drive similarities in imputed dropped-out
genes. Further, all methods except MAGIC only impute unobserved expression events (ze-
ros or near zeros), while in actuality, the dropout phenomenon affects the whole transcrip-
tome. Hence, imputation methods for scRNA-seq should also adjust non-zero expression
measurements in order to recover the true signal.
In the following sections, I will present a method I developed, called netSmooth, that uses
prior knowledge to temper noisy experimental data. RNA sequencing experiments pro-
duce transcript count data as a proxy for gene activity, which is not known a-priori, espe-
cially for experiments profiling unknown cell types. However, decades of molecular biology
research have revealed much about the principles of gene expression co-regulation. For in-
stance, genes coding for proteins that interact with one another are likely to be co-expressed
in cells (Bhardwaj and Lu, 2005; Fraser et al., 2004), and as such, protein-protein interac-
tion (PPI) databases (Szklarczyk et al., 2017; Lee et al., 2011a) describe genes’ propensity
for co-expression. I developed a method which uses diffusion on a PPI graph to network-
smooth gene expression values. Each node in the graph (a gene) has an associated gene ex-
pression value, and the diffusion represents a weighted averaging of gene expression values
among adjacent nodes in the graph, within each cell. This is done iteratively until conver-
gence, strengthening co-expression patterns which are expected to be present. Effectively,
this adjusts the observed gene expression values to more closely conform to the prior ex-
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pectation of co-expression patterns encoded by the PPI network. As I will show in the
following sections, incorporation of prior data from countless experiments in the pre-
processing of scRNA-seq experiments improves resistance to noise and dropouts. Similar
network based approaches have been used to extract meaningful information from sparse
mutational profiles (Hofree et al., 2013; Vandin et al., 2011), and indirectly on gene expres-
sion data by diffusing test statistics on the network to discover regulated gene candidates
(Dørum et al., 2011). netSmooth uses diffusion of gene expression values directly on the PPI
network for data denoising and imputation. In the absence of ground-truth, the parameter
of this method, the diffusion rate, may be optimized using data driven metrics. I applied
netSmooth to a variety of single cell experiments and compared its performance to other
selected imputation methods, namely scImpute andMAGIC. These methods represent
divergent ways of imputing the scRNA-seq data.
While I mention CIDR in this review, I do not include comparisons to CIDR in the
main text, alongside MAGIC and scImpute. This is because CIDR uses its own cluster-
ing procedure as a part of the imputation workflow. scImpute andMAGIC are agnostic
about post-imputation analysis, and therefore more readily lend themselves to compari-
son with netSmooth using a unified analysis framework (see section 2.2). For completeness,
the benchmark results of CIDR are included in the supplement (Figure A.11 on page 122,
Figure A.16 on page 124).
I also made netSmooth available as an R package, so that other researchers may use it on
their own data. At the time of writing, it has been downloaded more than 1,500 times*. It is
available on GitHub: https://github.com/BIMSBbioinfo/netSmooth and Bioconductor:
https://bioconductor.org/packages/release/bioc/html/netSmooth.html.
*http://bioconductor.org/packages/stats/bioc/netSmooth/
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2.2 Methods and Data
In this section, I will describe in detail the netSmoothmethod, as well as down-stream
analysis procedures and benchmarks which are implemented in the netSmoothR package
and will be used later in the results section, including data-driven metrics for optimizing
netSmooth’s parameter. Then I will describe the construction of the gene-gene network
which ships with the netSmoothR package, as well as other gene-gene networks constructed
for this analysis. Finally, I will describe the data sets that are analyzed in the results section,
and the parameter tuning of the comparison methods.
Overview of the method
The intuition behind the netSmooth algorithm is that gene networks encoding co-expression
patterns can be used to smooth scRNA-seq data, pushing its coexpression patterns in a bi-
ologically meaningful direction. Here, I demonstrate this using PPI networks, which are
predictive of coexpression (Fraser et al., 2004). I produced a PPI graph of high-confidence
interactions based on the PPI database STRINGdb (Szklarczyk et al., 2017), which I will
use in the next sections to demonstrate the utility of this method. In a later section, I will
also demonstrate the robustness of the method to other sources of gene networks, and its
sensitivity to the fidelity of the gene-gene interactions represented in the network.
netSmooth takes two inputs: (1) a gene expression matrix,N genes byM cells, and (2) a
graph where genes are nodes, and edges indicate genes which are expected to be co-expressed.
The edges may be weighed, indicating the strength or direction of a relationship; an edge
weight of 2 indicates stronger expected co-expression (e.g. correlation) than an edge weight
38
of 1, and an edge weight of−1 indicates negative expected co-expression (e.g. anticorrela-
tion), such as one gene being a repressor for another. The expression profile of each cell is
then projected onto the graph, and a diffusion process is used to smooth the expression val-
ues, within each sample, of adjacent genes in the graph (Figure 2.1 on the following page).
In this way, post-smoothing values of genes represent an estimate of activity levels based
on reads aligned to that gene, as well as those aligned to its neighbors in the graph. Thus, a
gene with a low read count (possible technical dropout), whose neighbors in the graph are
highly expressed, will get a higher value post smoothing. The rate at which expression val-
ues of genes diffuse to their neighbors is degree-normalized, so that genes with many edges
will affect their neighbors less than genes with more specific interactions. The diffusion is
done using a random walks with restarts (RWR) process (Vandin et al., 2011), where a con-
ceptual random walker starts in some node in the graph, and at each iteration moves to a
neighboring node with a probability determined by the edge weight between the nodes,
or, with some probability (the restart rate), restarts the walk from the original node. The
network-smoothed value is the stationary distribution of this markov process. The RWR
process has one free parameter, the restart rate. A low value for the restart rate allows diffu-
sion to reach further in the graph; a high restart rate will lead to more local diffusions.
Network diffusion through random walks
The netSmooth algorithm takes a graphG = {V,E}where V = {genei} is the set
of genes, andE = {(i → j)} is the set of edges between genes. The edge weights are
degree-normalized, so that each gene’s outgoing edges’ weights sum to 1. We then define a
process of random walk with restarts as in (Vandin et al., 2011), on the PPI graph, where a
conceptual random walker starts on a node in the graph (a gene/protein) and at each step
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Figure 2.1: The netSmooth algorithm takes a gene expression profile, and a gene network. The expression pro-
file of each sample is projected onto the network, where a diffusion process allows genes’ expression values to
be smoothed by their neighbors’. This is done for each cell independently of others. The end result is a network
smoothed gene expression matrix. This figure is reproduced from Ronen and Akalin (2018a)
walks to an adjacent node with the probability determined by the α times the edge weight.
Further, at each step, there is a probability of (1 − α) that the walker restarts to its original
node. (1 − α) is called the restart rate. This process is done starting at each node in the
graph.
Mathematically, given a graph defined by an adjacency matrixA[MxM ], whereAij is the
edge weight between gene i and gene j (and 0 for unconnected genes), and a vector f[Mx1],
where f ti is the probability that the walker is at node i at step t, the process is defined by
f t+1 = αAf t + (1− α)f 0.
This process is convergent, and the stationary distribution is easy to solve for, by setting
f t = f t+1:
f∞ = (1− α)(I − αA)−1f 0.
Hence, the random walk with restarts process is a diffusion process defined on the PPI
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graph, or through the diffusion kernel (smoothing kernel)
KαA = (1− α)(I − αA)−1
where (1− α) is the restart probability, andA is the (column normalized) adjacency matrix
of the PPI graph. Consequently, we define the network-smoothed expression profile
Esm = K
α
AE,
whereE[MxN ] is the normalized count values of theM genes in theN cells.
A robust clustering procedure
Clustering analysis features prominently in scRNA-seq analyses; whether recapitu-
lating known results or discovering new cell types, clustering cells by their gene expression
profiles is commonly used to identify distinct populations. While some approaches directly
take into account the zero-inflation of scRNA-seq data (Lin et al., 2017), other studies use
traditional methods (Deng et al., 2014). There is no standard method for clustering single
cell RNA-seq data, as different studies produce data with different topologies, which re-
spond differently to the various clustering algorithms.
In order to avoid optimizing different clustering routines for the different datasets I
benchmark on, and also in order to avoid optimizing clustering routines to the imputation
procedure, I have implemented a robust clustering routine based on clusterExperiment*
(Purdom and Risso, 2017), a framework for robust clustering based on a consensus of dif-
*Version 1.4.0, available from Bioconductor https://bioconductor.org/packages/release/bioc/
html/clusterExperiment.html
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ferent clustering algorithms, different parameters for these algorithms, and different views
of the data. The different views are different reduced dimensionality projections of the data
based on different techniques. No single clustering result will dominate the data, and only
cluster structures which are robust to different analyses will prevail. This procedure will
very likely be sub-optimal for each of the tasks we use it on, but this is by design; by averag-
ing over many clustering results, it represents an unbiased, reproducible cluster assignment.
The procedure I implemented using the framework is as follows:
1. Perform different dimensionality reduction techniques on the data
• PCA on the 500 most variable genes
– with 5 components
– with 15 components
– with 50 components
• Alternatively to PCA, t-SNE on the 500 most variable genes
– with 2 dimensions
– with 3 dimensions
• Select the most variable genes
– 100 most variable genes
– 500 most variable genes
– 1000 most variable genes
2. The PCA, t-SNE, and variable gene subsets make up different views of the data. On
each view of the data, perform PAM clustering* with K ranging from 5 to 10.
*Partitioning AroundMedioids, or k-medioids clustering, is a relative of k-means clustering, where each
cluster is represented by a medioid (an actual example) rather than the mean.
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3. Calculate the co-clustering index for each pair of samples. This is the proportion of
times the samples are clustered together, in the different clustering results based on
the different views and clustering parameters above.
4. Find a consensus clustering from the co-clustering matrix. This is done by construct-
ing a dendrogram using average linkage, and traversing down the tree until a block
with a self-similarity of at least 0.6, and a minimum size of 20 samples emerges. (in-
stead of using cutree).
5. Perform hierarchical clustering of the cluster medioids, with similarities based on
expression of the 500 most variable genes.
6. Perform a DE analysis between clusters that are adjacent in the hierarchy from (5),
and merge them if the proportion of genes that are found to be significantly differen-
tially expressed between them (adjP < .05) is less than than 0.1.
Using only the 500 most variable genes ensures the biological variation will dominate the
technical variation, and enhances the reproducibility of t-SNE (McCarthy et al., 2017).
Importantly, samples that at step (4) don’t have a high enough affinity to any emerging
cluster, will not be assigned to any cluster. The clustering is performed using the clus-
terExperiment::clusterSingle and clusterExperiment::clusterMany functions, the
consensus clustering is obtained using the clusterExperiment::combineMany function,
and the cluster merging (steps 5 and 6) using the clusterExperiment::makeDendrogram
and clusterExperiment::mergeClusters functions. For more details, see Purdom and
Risso (2017).
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Dimensionality reduction in the clustering procedure
In step (1) above, we cluster cells in a lower dimension embedding using either PCA
(Hastie et al., 2001) or t-SNE (van der Maaten and Hinton, 2008), in a dataset-dependent
manner. Different scRNA-seq datasets respond better to different dimensionality reduc-
tion techniques which are better able to tease out the biological cluster structure of the
data. In order to pick the right technique algorithmically, we compute the entropy in a 2D
embedding. We obtain 2D embeddings from the 500 most variable genes using either PCA
or t-SNE, bin them in a 20x20 grid, and compute the entropy using the discretize and
entropy functions in the entropyR package* (Hausser and Strimmer, 2014). The entropy
in the 2D embedding is a measure for the information captured by it. For the clustering
procedure, we pick the embedding, either PCA or t-SNE, with the highest information con-
tent.
Optimizing the smoothing parameters by cluster robustness
The netSmooth algorithm, given a gene network, has one free parameter - the restart
rate of the random walker, (1 − α). Alternatively, α is the complement of the restart rate.
An α = 0 indicates a unit restart rate and consequently no smoothing; an α = 1 cor-
responds to a random walk without restarts. Intermediate values for α result in increas-
ing levels of smoothing; the value of α determines how far random walks can go on the
graph before restarting, or how far along the network a gene’s influence is likely to reach. It
is tempting to optimize α with respect to the variable the experiment sets out to measure,
*Version 1.2.1, available from CRAN: https://cran.r-project.org/web/packages/entropy/index.
html
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e.g. if we set to identify clusters of different cell types, we might be tempted to pick the α
which results in the highest cluster purity. However, in many experiments the identity of
the samples is not known a-priori. Therefore, I propose a data driven workflow to pick a
sensible value for α.
One such data-driven statistic is the proportion of samples assigned to robust clusters;
the robust clustering procedure (see page 41) only assigns samples to clusters if they have a
strong enough affinity to it. It is able to leave samples without a cluster assignment. I pro-
posed to use the proportion of samples which can be clustered as a metric to optimize using
α. For two of the three datasets I will demonstrate below, picking the α that gives the high-
est proportion of cells in robust clusters, also gives the clusters with the highest purity index
(Figure A.2 on page 114). Importantly, this metric is entirely data-driven and does not re-
quire external labels, making it feasible for any scRNA-seq study. The results in the next
section all use the value of α picked to optimize proportion in robust clusters.
Benchmarks: cluster purity and adjusted mutual information
In order to benchmark the usefulness of clustering results where ground-truth
labels are known, I used a cluster purity index, and an adjusted mutual information score.
The cluster purity metric refers to the proportion of the samples in a cluster which are of
the dominant cell type in that cluster. The purity for cluster i is given by
Purityi =
∑
j∈Ci

1, if labelj = domi
0, otherwise
ni
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whereCi = {j|cellj ∈ clusteri}, labelj is the cell type of cellj , ni = |Ci| is the number of
cells in cluster i, and
domi = argmax
l
∑
j∈Ci

1, if labelj = l
0, otherwise
is the dominant cell type in clusterCi.
In addition to the cluster purity metric, I computed the AdjustedMutual Information
(AMI, Vinh et al. (2010)), an information theoretic measure of clustering accuracy which
accounts for true positives (two cells of the same type in the same cluster) being caused by
chance. The AMI between a clusteringC and the true labels L is given by
AMI(L,C) =
MI(L,C)− E[MI(L,C)]
max(H(L), H(C))− E[MI(L,C)] ,
whereMI(a, b) is the mutual information between labellings a and b,H(a) is entropy of
clustering a, andE[·] denotes the expectation.
Construction of the gene-gene network
The PPI graph from which the diffusion kernel was derived was constructed using data
from STRINGdb (Szklarczyk et al., 2017). For each pair of proteins, STRINGdb provides
a combined interaction score, which is a score indicating how confident we can be in the in-
teraction between the proteins, given the different kinds of evidence STRINGdb collates*.
We subset the links to only those above the 90th percentile of combined interaction scores,
*STRINGdb collects diverse evidence such as co-expression, biochemical interactions, genetic neigh-
borhoods, and even text mining, where proteins are assigned a likelihood to interact if they appear together
frequently in abstracts on PubMed. See https://string-db.org
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only keeping the 10%most confident interactions. For mouse that is 1,020,816 interactions
among 17013 genes. For human, 852,722 interactions among 17467 genes.
Other gene networks were constructed using HumanNet (Lee et al., 2011a). As the name
suggests, this is a functional gene network of Human genes, and so I only used it for the
human data (see below). The HumanNet graph isn’t as dense as the STRINGdb graph,
and so requried no filtering.
The data sets
The results in the next section use data from the following three publically available
scRNA-seq datasets. The hematopoiesis dataset (Nestorowa et al., 2016) was obtained from
the Gene Expression Omnibus (Edgar et al., 2002). The embryonic (Deng et al., 2014) and
glioblastoma (Patel et al., 2014) datasets were obtained from conquer (Soneson and Robin-
son, 2017), a repository of uniformly processed scRNA-seq datasets. The datasets are avail-
able, see Table 2.1.
Dataset URL
Hematopoiesis https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81682
Embryonic cells http://imlspenticton.uzh.ch/robinson_lab/conquer/data-mae/GSE45719.rds
Glioblastoma http://imlspenticton.uzh.ch/robinson_lab/conquer/data-mae/GSE57872.rds
Table 2.1: Datasets and availability. This table is reproduced from Ronen and Akalin (2018a)
MAGIC and scImpute parameters
For all the results presented in section 2.3 on the next page, scImpute was run using
the default parameters (drop_thre = 0.5). For MAGIC, we used values for the diffusion
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time parameter (T = {1, 2, 4, 8, 16}). Unlike netSmooth, for MAGIC the proportion of
samples in robust clusters and the cluster purities were anti-correlated; thus we picked the
one that gave the best cluster purities as the best MAGIC parameter. The chosen T values
are given in Table 2.2. We usedMAGIC version 0.1* and scImpute version 0.0.2†.
Dataset Optimal T
Hematopoiesis 1
Embryonic cells 4
Glioblastoma 2
Table 2.2: Optimal diffusion time values for MAGIC. This table is reproduced from Ronen and Akalin (2018a)
The netSmooth R package
The analysis was done using the netSmoothR-package (Ronen and Akalin, 2018b), which
is available online: https://github.com/BIMSBbioinfo/netSmooth. The netSmoothR
package was included in the 3.7 release of Bioconductor: https://bioconductor.org/
packages/release/bioc/html/netSmooth.html and has since been downloaded over
1,500 times. It is available under a GPL version 3 (or later) license.
2.3 Results
In the following pages, I will show the utility of netSmooth on three analysis tasks, us-
ing three different scRNA-seq datasets studying three different cellular systems: Hematopoiesis,
Embryonic development, and cancer. These results were published in Ronen and Akalin
(2018a), and are reproduced here with minor edits for clarity.
*Available from GitHub: https://github.com/pkathail/magic.
†Available from GitHub: https://github.com/Vivianstats/scImpute.
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netSmooth improves cell type identification from scRNA-seq
Nestorowa et al. (2016) sequenced the transcriptomes of 1645 mouse hematopoi-
etic stem/progenitor cells (HSPCs), and also assayed them using flow cytometry, FACS-
sorting them into 12 commonHSPC phenotypes. This presents an atlas of the hematopoiesis
process at a single cell resolution, showing the differentiation paths taken by E-SLAM
HSCs as they differentiate to E, GM, and L progenitors. The authors of this study demon-
strate that upon clustering the data, some clusters corresponds to cell types. However, the
clusters are not noise free and do not fully recapitulate cell type identity. We obtained clus-
terings of the cells from the normalized counts, as well as after application of netSmooth,
MAGIC (van Dijk et al., 2017), and scImpute (Li and Li, 2017), using a robust cluster-
ing procedure based on the clusterExperimentR package (Purdom and Risso, 2017) (See
Section 2.2 on page 38). After clustering, we used the edgeR-QLF test (Robinson et al.,
2010) to identify genes that are differentially expressed in any of the discovered clusters.
Figure 2.2a,b on page 50 shows the log-transformed expression values of the 500 most dif-
ferentially expressed genes, before and after application of netSmooth. The column anno-
tations indicate the FACS-sorted cell type of each cell, as well as the cluster assignment ob-
tained from the robust clustering procedure, using the netSmoothR package. The figure
suggests that the network-smoothing effect is subtle on the individual genes, as difference
between the heatmaps is negligible visually. Figure 2.2c,d shows the same for the MAGIC
and scImpute-preprocessed data, respectively. MAGIC seems to do the strongest transfor-
mation to the data, as is also seen in lower dimension embeddings (Figure A.3 on page 115,
Figure A.4 on page 116).
As this dataset has cells with labels independent of the RNA-seq (FACS-sorted phe-
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Figure 2.2: Cells were clustered using the robust clustering procedure, and the log-transformed expression values of
the 500 most differentially expressed genes (by edgeR-QLF test adjusted P value) in any of the discovered clusters
are shown in a heatmap, as well as cluster assignments and FACS-sorted cell types. A) raw (no imputation), B) after
application of netSmooth, C) missing values imputed using MAGIC D) missing values imputed using scImpute. This
figure is reproduced from Ronen and Akalin (2018a).
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notypes), it presents us with an opportunity to compare the gene expression levels (as
measured by RNA-seq), to a meaningful phenotypic variable, i.e. the cell type. The cell
type discrimination of a clustering result is compared using a cluster purity metric and
and the adjusted mutual information (AMI). The cluster purity measures how cell-type
specific clusters are by comparing homogeneity of the external labels (FACS-defined cell
types), within clusters provided by scRNA-seq data. AMI is a chance-adjusted information-
theoretic measure of agreement between two labellings. This method accounts for arti-
ficially high mutual information between external labels and clusters when there is large
number of clusters (see section 2.2 on page 38 for details on metrics). I also measured num-
ber of cells in robust clusters as quantitative metric. The robust clustering procedure allows
cells to be omitted (not be assigned to a cluster) if they cannot be placed in a cluster across
multiple clustering methods and/or parameters (see section 2.2 on page 38). MAGIC-
processed data leads to a larger proportion of cells assigned to robust clusters, while netSmooth
and scImpute lead to a reduction in the clustering robustness metric (Figure 2.3a). All three
methods are able to discover some novel clusters in the data with high purity (Figure 2.3b).
A closer inspection shows that MAGIC achieves this through a proliferation of small clus-
ters, which are not, so far as I could judge, meaningful beyond chance. This is evidenced by
the lower adjusted mutual information score (Figure 2.3c). netSmooth-preprocessed clusters
achieve a higher AMI score, which, while modest, is biologically relevant.
netSmooth improves embryonic development expression patterns in scRNA-
seq
Next, I demonstrate netSmooth on 269 isolated cells frommouse embryos at different
stages of pre-implantation development between oocyte and blastocyst, as well as 5 liver
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Figure 2.3: Hematopoiesis clustering metrics. A) The proportion of cells which were assigned to robust clusters. B)
cluster purity (proportion of dominant cell type) for the robust clusters. netSmooth produces the most pure clus-
ters in terms of cell types. C) AMI of the clustering results obtained after application of each of the methods. Only
netSmooth increases the AMI between the clustering and the cell types. This figure is reproduced from Ronen and
Akalin (2018a).
cells and 10 fibroblast cells sequenced and published by Deng et al. (2014). The authors of
this study demonstrated that lower dimension embeddings capture much of the develop-
mental trajectory (Figure 2.4a, Figure A.5a, A.6a). I used netSmooth, MAGIC, and scIm-
pute on the scRNA-seq data to impute possible dropouts and reduce the noise. netSmooth
and scImpute preserve most of the structure of the data, while MAGIC seems to push the
data onto a completely different manifold (Figure 2.4 on page 54, Figure A.6 on page 118).
I used the robust clustering procedure to obtain clusters, and computed the cluster purity
and AMI metrics. netSmooth enabled the clustering procedure to place more of the sam-
ples into robust clusters (Figure 2.5a), and as in the hematopoiesis case, netSmooth is able
to assist in identifying the developmental stage or tissue that cells belong to better than the
other methods, as evidenced by the higher cluster purities (Figure 2.5b) and AMI (Figure
2.5c). scImpute also improves the cluter purity and AMI metrics (Figure 2.5b,c), and is not
easily differentiable from netSmooth in the PCA scatter plot (Figure 2.4 on page 54). The
netSmooth results are marginally better, which hints at an equivalence in the recovered sig-
nal quality between the two methods, netSmooth’s quasi-imputation incorporating pri-
ors, and scImpute’s linear model-based imputation. scImpute achieves this by reducing the
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overall 0-count genes significantly more than netSmooth (Figure A.7 on page 119), which
suggests that incorporating priors the way netSmooth does can achieve similar results to data
imputation, without actually imputing too much. The smaller change in the proportion
of 0-count genes following netSmooth than scImpute (Figure A.7 on page 119) shows that
netSmoothworks primarily by smoothing values of genes with measured expression, as op-
posed to imputing suspected missing counts. This suggests a lesser transformation of the
data, such as through application of netSmooth, can uncover much of the true signal hidden
in the noisy data.
netSmooth aids identification of glioblastoma tumors
In a final analysis, I demonstrate applicability of netSmooth to cancer research. Patel
et al. (2014) generated scRNA-seq data of 800 cells from 5 glioblastoma tumors and 2 cell
lines. Lower dimension embedding plots show that cells from different tumors or cell lines
generally group together, but some are not wholly distinguishable from other tumors (Fig-
ure 2.6a, A.8a, A.9a). Further, the two cell lines group closer to each other than the other
patient samples. After applying netSmooth to the data, tumors become easier to distinguish
in a lower dimensional embedding (Figure 2.6b), i.e. netSmooth improves assignment of
each cell to its tumor, cell line, or clone of origin. Again, scImpute also leads to similar re-
duced dimension embedding (Figure 2.6d), while MAGIC distorted the data more than
the other methods (Figure 2.6c). I used the robust clustering procedure before and after
netSmooth, MAGIC, and scImpute. Only MAGIC increases the robustness of the clusters
found in the data (Figure 2.7a), but netSmooth leads to the most pure clusters, in terms of
tumor or cell line of origin (Figure 2.7b, Figure 2.7c).
Tumor or cell line of origin is an imperfect proxy for phenotypical variation in cancer
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Figure 2.4: 2D PCA plots of the embryonic development dataset A) no preprocessing, B) after application of
netSmooth, C) after imputing missing values with scImpute, and D) after application of MAGIC. This figure is re-
produced from Ronen and Akalin (2018a).
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Figure 2.5: The Embryonic development dataset. A) The proportion of cells which were assigned to robust clus-
ters. All three methods lead to better clusterability, with MAGIC having the strongest effect. B) cluster purity (pro-
portion of dominant cell type) for the robust clusters. netSmooth produces the most pure clusters in terms of cell
types. C) Adjusted mutual information of clusterings and cell types. Only netSmooth increases the AMI over the
non-preprocessed data. This figure is reproduced from Ronen and Akalin (2018a).
cells, because some cells cluster by cell type rather than tumor of origin, demonstrating the
heterogeneity in these glioblastoma tumors and similarities across origins (Patel et al., 2014).
Nevertheless, I chose to compute cluster purity based on the cell origin rather than other
labels which might be assigned to them, as it is the only ground truth variable that is inde-
pendent of the RNA-seq experiment. Further, cells do group by origin (Figure 2.6 on the
next page, Figure A.8 on page 120), and identification of origin is an interesting question in
its own right in the field of cancer genomics, particularly for heterogeneous tumors such as
these.
Sensitivity to the network
I set out to ensure that the results are not an artifact of the network structure, i.e. that
the actual links between genes. We expect netSmooth not to perform well when using net-
works with similar characteristics, but where edges do not represent real interactions. To
that effect, I constructed 20 random networks by keeping the same graph structure of the
real PPI graph, but shuffling the gene names. Thus, these random networks share all the
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Figure 2.6: t-SNE plots of the glioblastoma dataset A) no preprocessing, B) after application of netSmooth, C), using
MAGIC, and D) after application of scImpute. This figure is reproduced from Ronen and Akalin (2018a).
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Figure 2.7: Imputation performance for the glioblastoma dataset. A) The proportion of cells which were assigned to
robust clusters. netSmooth, MAGIC, and scImpute all increased the proportion of cells that are assigned to robust
clusters, with MAGIC leading, netSmooth in second place, and scImpute in third. B) cluster purity (proportion of
dominant cell type) for the robust clusters. netSmooth produces the most pure clusters in terms of tumor or cell line
of origin. C) AMI of the clustering results obtained after application of each of the methods. This figure is reproduced
from Ronen and Akalin (2018a).
characteristics of the real network (degree distribution, community structure, etc.), except
for the true identity of the nodes. I then used those networks as inputs to netSmooth and
ran the benchmarks as before on the hematopoiesis dataset. Using random networks as an
input to netSmooth gives cluster purities distributed around a mode given by the cluster
purities of the raw data, while the cluster purities given from using the real PPI network
lie at the extreme edge of the distribution (Figure 2.8a). In other words, random networks
are helpful or detrimental to cluster purity with approximately the same likelihood— and
using the real gene network, we get an improvement as high as the best random networks
can achieve. Further, most random networks result in fewer samples belonging to robust
clusters (Figure 2.8b), that is, network-smoothing gene expression on random gene-gene
networks tends to reduce the clusterability of the data, but much less so when using real
gene-gene networks. Finally, I also calculated the adjusted mutual information of cluster-
ings resulting from the randomized networks (Figure 2.8c). Again, most shuffled networks
produce worse clusterings, with the real network outperforming all of them, as well as the
no-smoothing case. I.e., network-smoothing gene expression on random gene networks
tends to produce cluster results which are srictly worse than the raw data, while network-
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Figure 2.8: Performance of netSmooth with randomized networks. A) The median cluster purity achieved with
the random networks. The real network outperforms the random ones, which result in cluster purities distributed
around the purity given without using netSmooth. B) The proportion of samples assigned to robust clusters using
the random networks as well as the real one. While all networks result in fewer samples robustly clustered (in the
hematopoiesis dataset), the real network outperforms most random networks. C) The Adjusted Mutual Information
achieved with the randomized networks. Most random networks produce clusterings with a worse AMI than using
no network-smoothing. netSmooth with the real network structure produces the clustering result with the best AMI.
This figure is reproduced from Ronen and Akalin (2018a).
smoothing on a real gene network improves the biological relevance of the clusters. This
underlines the importance of also calculating the AMI, and not only the cluster purity, as
cluster purity is sometimes improved using random networks (Figure 2.8a), but this is likely
due to a proliferation of clusters some times. These results demonstrate that it is indeed the
information contained in the PPI graph which enables netSmooth to transform the gene ex-
pression matrix in a more biologically coherent direction, and that the transformation we
see can not be explained simply by the network topology, i.e. it only works if the edges in
the network are real (network-adjacent genes really are co-regulated), and if so, it is worth
doing.
Using other networks with netSmooth
In addition to using an unweighed (where all edge weights are 1), undirected (where
all edge weights are positive) network from STRINGdb (see page 46), I constructed other
gene networks and used them as inputs to netSmooth. I created a directed gene network
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Figure 2.9: Cluster purities after applying netSmooth with different input networks. Raw refers to no smoothing,
non-directional is the same as the results shown in previous sections. Directional refers to a gene network where
inhibitory relationships have negative edge weights, and cell-type specific refers to a gene network of only genes
which are known to have cell-type specific expression patterns. This figure is reproduced from Ronen and Akalin
(2018a).
from only those edges in STRINGdb which are marked as activating or inhibiting*. I set
the edge weights of the activating interactions to+1, and−1 for the inhibiting interac-
tions, allowing gene expression values to be adjusted downwards for genes whose known
antagonists are highly expressed. After smoothing, I set all negative smoothed expression
values to 0. I also constructed a gene network from STRINGdb using only genes that are
known to demonstrate cell-type specific expression. In order to obtain a list of genes with
such cell-type specific expression patterns from the Expression Atlas (Petryszak et al., 2016),
I used only the genes which show a cell-type specific expression with a mean transcripts per
kilobase million (TPM) of at least 1 in some cell type, and used the subset of STRINGdb
network containing those genes as an input to netSmooth. Both of those modified graphs
perform similarly to the undirected graph from STRINGdb (Figure 2.9, Figure A.10a, Fig-
ure A.10b on page 122), demonstrating that netSmooth is able to use priors from different
types of experiments in order to improve clustering of scRNA-seq.
I also considered other sources for the gene network. I constructed a gene network from
HumanNet (Lee et al., 2011b), a functional gene network where edges denote interactions
*Most interactions in STRINGdb do not specify the direction, or nature of the interaction
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Figure 2.10: Cluster purities after applying netSmooth with different input networks. Raw refers to no smoothing,
STRINGdb is the same as the results shown in previous sections, and HumanNet refers to a gene network con-
structed from the HumanNet database. This figure is reproduced from Ronen and Akalin (2018a).
between two genes. I constructed a smoothing graph by taking all edges fromHumanNet,
and producing a graph where all edge weights are set to 1. I then used this graph as an in-
put to netSmooth on the glioblastoma dataset. It performs similarly to the network from
STRINGdb (Figure 2.10, Figure A.10c on page 122), demonstrating that other sources for
gene interactions may also be used by netSmooth to improve clustering results of scRNA-
seq. Taken together with the results in the previous subsection, netSmooth improves scRNA-
seq analysis, contingent on the priors (gene networks) being real.
As more scRNA-seq experiments are published, context-specific networks will be made
possible to create, potentially improving netSmooth’s performance. The networks I have
shown above have links between genes which are known in a general context, but scRNA-
seq experiments might uncover previously unknown cell-type specific gene interactions,
which could contribute to the information uncovered by network smoothing. Here, I have
demonstrated that even the general-context networks I have used are able to assist in identi-
fying specific cell types from noisy scRNA-seq datasets.
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2.4 Discussion
Single cell RNA sequencing technology provides whole-genome transcriptional
profiles at unprecedented throughput and resolution. However, high variance and dropout
events that happen in all current scRNA-seq platforms complicate the interpretation of
the data. Methods that treat 0 counts as missing values and impute them based on nonzero
values in the data may amplify biases in the data.
I presented netSmooth as a preprocessing step for scRNA-seq experiments, overcoming
these challenges by the use of prior information derived from protein-protein interactions
or other molecular interaction networks. I demonstrated that netSmooth assists in several
standard analyses that are common in scRNA-seq studies. This procedure enhances cell
type identification in hematopoiesis; it elucidates time series data and assists identification
of the developmental stage of single cells. Finally, it is also applicable in cancer, improving
identification of tumor of origin for glioblastomas. In addition, I showed that the network
smoothing parameter can be optimized by cluster robustness metrics, providing a data-
driven way to pick the parameter when there are no other external labels to distinguish cells.
I demonstrated that netSmooth can use prior information from different sources in order to
achieve this.
I compared netSmoothwith scImpute, a statistical genome-wide imputation method,
andMAGIC, a genome-wide data smoothing algorithm, and demonstrated that while
scImpute andMAGIC reduce the dropout phenomenon more than netSmooth does, netSmooth
outperforms them in amplifying the biological/technical variability ratio. Thus, this is an-
other voice added to the debate on the biological / technical origins of the dropout prob-
lem, and whether or not imputation is the best way to handle it. netSmooth provides clus-
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ters that are more homogeneous and have higher adjusted mutual information (AMI) with
respect to cell types. Although, in some cases data processed byMAGIC produces more
robust clusters, the clusters returned after MAGIC processing do not have higher AMI or
cluster purity. Higher robustness achieved byMAGIC processing might be due to the fact
that the algorithm reinforces local structures too much in the data and produces artificially
similar expression profiles between cells. Comparisons to CIDR (Figure A.11 on page 122,
Figure A.16 on page 124) also show inferior performance to netSmooth.
In most of the benchmarks I ran, scImpute shows similar performance to netSmooth.
The former relies on other data points in order to impute missing data, and the latter per-
forms a quasi-imputation based on priors from other experiments. The analysis shows that
netSmooth affects the dropout rate less than scImpute, while uncovering slightly more of
the biological signal. This happens across the different overall dropout rates in the 3 exper-
iments I profiled, indicating that netSmooth can achieve better results, with less obtrusive
transformations of the data, than the imputation methods, across a range of experimental
conditions.
Finally, netSmooth is a versatile algorithm that may be incorporated in any analysis pipeline
for any experiment where the organism in question has a high quality gene network avail-
able. The algorithm is applicable to any omics data set that can be constructed as a genes-
by-samples matrix, such as proteomics, SNPs, DNAmethylation, and copy number vari-
ation. In Chapter 3, I will demonstrate another netSmooth use case, where I will show that
network smoothing of mutations prior to multi-omics integration improves the survival
prediction abilities of our models in cancer. In addition, most of the computational load of
network smoothing can be done ”off-line”. As such it scales well with the number of cells,
which is likely to increase in future scRNA-seq experiments. I have made available an R
package to that end, which is available on GitHub: https://github.com/BIMSBbioinfo/
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netSmooth, and Bioconductor: https://bioconductor.org/packages/release/bioc/
html/netSmooth.html.
63
64
It was six men of Indostan
To learning much inclined,
Who went to see the Elephant
(Though all of them were blind),
That each by observation
Might satisfy his mind
John Godfrey Saxe, The Blind Men and the Elephant
3
Cancer sub-typing using priors from other
experiments and deep learning multi-omics
data integration
Analyzing data from a single ”omic” experiment, one would be wise to remember the
parable of the blind men and the elephant; when each blind man grabs a different part of
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the elephant, they will hardly agree on what an elephant is. In the same way, looking only
at DNAmutations, or only at mRNA expression, two oncologists might not agree on what
kind of tumor they are examining. Different omics assays may reveal different aspects of
the same biological processes, sometimes in redundant ways, other times complementary
to one another. Large scale initiatives such as The Cancer Genome Atlas (TCGA) have se-
quenced thousands of tumors using different omics protocols, empowering multi-faceted
analysis of different cancer types. The TCGA data has enabled the field of cancer genomics
to grow to maturity; since the first publication of the TCGA research network uncovered
three previously unknown critical signaling pathways implicated in glioblastoma (Cancer
Genome Atlas Research Network et al., 2008), and through the pan-cancer atlas (Hoadley
et al., 2018) paper which revealed cancers arrising in different tissues can arrise from the
same cells, the TCGA has made clear the clinical benefits that come from defining cancer
sub-types using multi-omics data.
Artificial neural networks (ANN) have shown promise in many bioinformatics
problem types, from sequence analysis through molecular structure prediction. In this
chapter, I present a novel method I developed using ANNs as the backbone of a latent vari-
able multi-omics integration framework. While the method is general, I demonstrate its
utility in the study of colorectal cancer subtypes, and the assignment of colorectal cancer
models (cancer cell lines) to sub-types. The following is adapted from Ronen et al. (2018), a
paper on which I was the lead author. At the time of writing, the paper is undergoing peer-
review, and the pre-print is available on bioRxiv.
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Figure 3.1: Blind monks examining an elephant by Itcho Hanabusa. Ukiyo-e print illustration from Buddhist parable
showing blind monks examining an elephant. Each man reaches a different conclusion based on which part of the
elephant he has examined.
3.1 Introduction
Colorectal cancer (CRC) is a leading cause of death in the developed world. In the
United States alone, it is predicted to cause over 50,000 deaths in 2019, second only to lung
cancer (American Cancer Society, 2019). With over 140,000 new cases in the US yearly, this
represents a five year survival rate of approximately 65%. While the mortality trend is de-
creasing for patients diagnosed at an age of 56 and up, most likely due to improvements
in screening, patients diagnosed before the age of 55 face worsening prospects than before,
underlining the poor treatment options available to CRC patients, with surgery being the
most common treatment. This represents a pressing need for better understanding of CRC
sub-types, as patient populations with distinct molecular disease sub-types are likely to ben-
efit from drug discovery trials targeting their disease.
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The CRC label encompasses different diseases with distinct morphological and molecu-
lar characteristics. Commonmolecular aberrations include mutations in the WNT,MAPK,
TGF-β, and PI3K–AKT signaling pathways (Parsons et al., 2005; Fearon, 2011; The Can-
cer Genome Atlas Network, 2012). These mutations occurr through different mechanisms:
chromosomal instability (CIN), which is characterized by many copy number alterations
(CNA), and microsatellite instability (MSI), leading to hyper-mutated tumors, but with
mostly diploid genomes (low CNA) (Müller et al., 2016). These mechanisms may be driven
by mutations in e.g. DNAmismatch repair (MMR), or through epigenetic alterations (Lao
and Grady, 2011). Müller et al. (2016) analyzed the colorectal cancer TCGA cohort and clas-
sified them into hyper-mutated (≈ 16%) and non hyper-mutated (≈ 84%) cancers. The
hyper-mutated cancers have MSI. The non-hypermutated, microsatellite stable (MSS) can-
cers, are characterized by CIN, with high occurance of CNA, and mutations in the APC,
TP53, KRAS and BRAF genes. Some of the tumors also have the CpG island methylator
phenotype (CIMP, Toyota et al. (1999)), which epigenetically silences tumor suppressors
andMMR genes, confirming that the TCGA data was representative of current under-
standing of CRC.
The gold standard in molecular sub-typing of CRC is the Consensus Molecular Sub-
types (CMS), developed by the colorectal cancer subtyping consortium (Guinney et al.,
2015). This classification system, based on gene expression profiling of thousands of CRC
tumors, divided tumors into four subtypes with distinguishing features. The CMS1 sub-
type is defined by hypermutation, microsatellite instability and strong immune activation;
CMS2 is defined by chromosomal instability (CIN), WNT andMYC signaling activation;
CMS3 is defined by metabolic dysregulation; and CMS4 is defined by growth factor β ac-
tivation, stromal invasion, and angiogenesis. Approximately 13% of the tumors do not
belong to a consensus subtype, as they have mixed gene expression signatures. They may
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represent distinct tumor types, or samples with intra-tumor heterogeneity. While the CMS
classification is based on gene expression, follow-up analysis of the tumors revealed distinct
copy number profiles, mutation frequencies, and methylation profiles (Guinney et al., 2015)
(Figure B.6 on page 130), indicating that other omics types contain important information.
I developed a multi-omics integration method that can incorporate gene expression,
copy number, and mutation data to identify CRC subtypes, with implications for patient
stratification. I used it to refine the CMS classification system for CRC tumors, and to as-
sign colon cancer cell lines to the different sub-types. As xenografts and 3D organoid tumor
models become more widespread, the method will be able to match those to sub-types as
well. This will be highly useful, as these have been shown to predict drug response in pa-
tients (Vlachogiannis et al., 2018). By leveraging multi-omics datasets, CRC samples that
can not be associated to a CMS subtype are also assigned to an appropriate subtype. In ad-
dition, multi-omics signatures, incorporating gene expression, point mutations and copy
number alterations, are a direct output of the method, and will not need to be generated
post-hoc, e.g. by examining mutation rates in groups defined by gene expression profiles, as
in the CMS.
The method I developed uses deep learning to perform latent factor analysis, an unsu-
pervised learning technique. Genomic assays are high-dimensional (tens of thousands of
genes), and high-dimensional spaces are challenging to analyze. This problem is further ex-
acerbated by the introduction of multiple assays from different omics platforms. Latent fac-
tor analysis seeks to find a lower dimension representation of the data, which preserves the
important structure and patterns therein. This is sometimes referred to as dimensionality
reduction. By describing the data using a handful of latent factors, rather than tens of thou-
sands of genes, down-stream analysis, such as distance calculations and clustering, are sim-
plified (Trunk, 1979). It is further desirable that latent factors be interpretable in the biolog-
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ical context, i.e. that the patterns summarized by a latent factor implicate cellular processes.
The workhorse for latent factor analysis for multi-omics, as well as general data analysis,
has been matrix factorization (Tini et al., 2017). Latent factor analysis for multi-omics data
typically includes concatenating the different omics data to a single matrix and applying a
well-known matrix factorization algorithm, sometimes with weighting of the individual
data sets. Multifactor analysis (MFA, de Tayrac et al. (2009)) and iCluster+ (Mo et al., 2013)
are examples of such methods. Some such algorithms, such as MFA, impose orthogonality
of factors, i.e. that the factors explain disjoint underlying processes, as in PCA. Orthogo-
nality might be conceptually appealing, but is not a biological necessity. Orthogonal latent
factors may be the best for statistical reconstruction of a dataset, and still be biologically
difficult to interpret. One feature of latent factor representations which aids biological in-
terpretability is sparsity, i.e. each latent factor only depends on a few of the input genes, and
each sample is described by only a handful of latent factors. Sparsity in the relationship be-
tween input genes and latent factors simplifies the task of biological interpretation of the
model, that is, implicating known biological processes underlying the latent factors; sparsity
in the relationship between latent factors and samples simplifies down-stream analysis such
as clustering.
While it is reasonable to expect that the latent factors describing the data be of much
lower dimensionality than the genome-scale input data, it is an open question just how low
the dimensionality should be. Heuristics to pick the number of latent factors have been
proposed by method designers. PCA andMFA typically suggest an elbowmethod, where
latent factors are ordered by their variance explained, and the user determines an elbow
point in the graph, discarding latent factors with a low variance explained. MOFA formal-
izes this heuristic by starting the fitting process with a high number of latent factors, and
during training, discarding ones with a variance explained below a pre-set threshold (with
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a default value of 2%). iCluster+’s heuristic comes from its k-means roots, i.e. one tends to
set the number of latent factors toK − 1where K is the number of clusters one expects to
find. Recently, a large-scale study of latent factor methods (Buhai et al., 2019) has demon-
strated the desirability of specifying more latent factors than are expected to exist in the
data. Specifically, it was shown that using more latent factors than are needed, can compen-
sate for shortcomings in the training algorithm, and improve log-likelihood and recovery of
ground-truth latent factors. Hence, it is desirable to have a latent factor method that is able
to learn a large number of latent factors efficiently from the data.
I developed my method building on disentangled variational autoencoders (β-VAE)
(Higgins et al., 2017), an unsupervised deep learning architecture which has been shown
to generalize well and produce disentangled representations. A similar method has been
shown to be able to stratify cancers by their tissue type based on gene expression profiles (Way
and Greene, 2017), and other autoencoder architectures have been used to integrate multi-
modal data in robotics (Cadena, Dick, and Reid, Cadena et al.), as well as protein func-
tion prediction (Gligorijević et al., 2018) and small molecule characterization (Winter et al.,
2019). I use a multi-modal, stacked β-VAE to extract latent factors which are important
for defining subtypes and predicting patient survival. I call the method, ”Multi-omics
Autoencoder Integration”, or,maui.
In this chapter, I will describemaui and compare its performance to other state-of-
the-art multi-omics data integration methods. I will use it to refine the CMS classification
system, and to match cancer cell lines to the different sub-types. I will also demonstrate
how combining the two methods I developed, netSmooth (Chapter 2) andmaui, results in
even better survival prediction for CRC patients.
I mademaui available as a Python package, so that other researchers may use it with
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their own data. At the time of writing, it has been downloaded more than 6,000* times.
It is easily obtainable from GitHub (http://github.com/bimsbbioinfo/maui), and PyPI
(https://pypi.org/project/maui-tools/).
3.2 Methods and Data
Data
I downloaded data for tumors from the TCGA-COAD (n=389) and TCGA-READ
(n=130) project designations of the Genomic Data Commons † using the TCGAbiolinks
R package (Colaprico et al., 2016). I downloaded the CMS annotations for the TCGA tu-
mors from the Colorectal Cancer Subtyping Consortium (CRCSC) ‡. Table 3.1 summarizes
the subtype information. The gene expression data (mRNA) is HTSeq - FPKM.Muta-
tions were downloaded as MAF files, filtered to include non-synonymous mutations only,
and represented as a binary mutation matrix wheremij = 1 if and only if gene i carries a
non-synonymous mutation in sample j. Copy number alterations are GISTIC (Beroukhim
et al., 2007) calls by gene, represented as a real-valued matrix where cij is the GISTIC seg-
ment mean for the segment containing gene i in sample j. Cancer Cell Line Encyclopedia
data was obtained from the CCLE portal §, and is the same data types as the TCGA data,
with the exception that transcriptome profiles are RPKM-normalized and not FPKM. I
considered 54 cancer cell lines originating from the colon.
I considered only tumors (from TCGA) and cancer cell lines (CCLE) which have ”com-
plete data”, that is, available measurements in all three assays: gene expression, SNVs, and
*https://pepy.tech/project/maui-tools
†https://portal.gdc.cancer.gov
‡http://sagebionetworks.org/research-projects/colorectal-cancer-subtyping-consortium-crcsc/
§https://portals.broadinstitute.org/ccle
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CNVs.
CMS label Description # Samples
CMS1 MSI Immune 61
CMS2 Canonical 175
CMS3 Metabolic 60
CMS4 Mesenchymal 123
Total with CMS label 419
Without CMS label 100
Total 519
Table 3.1: Summary of TCGA tumors’ CMS labels. This table is reproduced from Ronen et al. (2018).
I used gene-wise MAD statistic, computed directly on the raw data described above, in
order to select the most informative genes. For the comparisons withMOFA and iCluster+,
I used the 1,000 genes with the highest MAD for gene expression, 200 for mutations, and
100 for copy number alterations, for a total of 1,300 input features. I selected the features
so strictly in order to make a comparison against iCluster+ viable, and with a larger feature
space iCluster+’s runtime would become untenable (Table 3.2 on page 91).
For the final clustering analysis, I used a larger feature set, with 5,000 gene expression val-
ues, 500 mutations and 500 CNVs for a total of 6,000 features, taking advantage ofmaui’s
neural network architecture which allows for larger feature spaces to undergo feature selec-
tion as part of the training.
I fit maui using all TCGA samples, both with and without a CMS label (n=519, Table 3.1)
as well as colon-derived cancer cell lines (n=54), for a total training set size of 573. For the
analysis that depends on a CMS label being available, the input features were the latent
factors, and the samples only those TCGA samples with a well-defined CMS label (n=419,
See Table 3.1).
All input features were scaled and centered prior to feeding to the neural network, using
batch normalization. Prior to this scaling, mutation data was binary, CNV data GISTIC
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calls, and gene expression counts were RPKM/FPKM values (Mortazavi et al., 2008) which
were scaled and centered. TCGA and CCLE gene expression matrices were first scaled and
centered individually, and then concatenated and scaled jointly, in order to filter out the
”batch effect” of CCLE vs. TCGA data and enable mapping of tumors and cell lines to the
same space. This means that, for a trainedmauimodel, when new, unseen samples are to
be mapped onto the latent factor space, they must first be normalized in this way to fit the
distribution of the training data.
Latent factor model for multi-omics data
Starting from different data matrices xi from different modalities, we call the full
multi-omics data set x = [x1, x2, ..., xm].
We define a generative model x ∼ p(x|z). Graphically, our model looks like Figure 3.2a,
a Bayesian latent variable model where the variation in the data x is explained by the varia-
tion in a smaller set of latent factors, z. In order to infer the latent variables z ∼ p(z|x), as
p(z|x) is generally intractable, we proceed with a variational Bayes framework, i.e. approx-
imating p(z|x) ≈ qθ(z|x), where qθ(z|x) is a simple class of distribution, and minimizing
the Kullback-Leibler divergenceDKL(qθ(z|x)‖p(z|x)). This is equivalent to maximizing
the Evidence Lower Bound (ELBO) (Blei et al., 2016):
ELBO = Eq[log(pφ(x|z))]−DKL(qθ(z|x)‖pφ(z)).
We follow Kingma andWelling (2013) and re-parameterize zli as
zli = µi + σil
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where
l ∼ N (0, I),
which allows us to construct the Autoencoder shown in Figure 3.2b.
The first half of the autoencoder, leading from x to z (the ”encoder”) is a neural net-
work which will be trained to compute qθ(z|x), that is, θ denotes the weights of the en-
coder network. The second half, the ”decoder” network, is a neural network which will be
trained to compute pφ(x|z), so φ denotes the weights of the decoder network. Thanks to
the reparametrization of z, the path from x to xˆ is differentiable, via backpropagation, in θ
and φ, and thus we can use gradient descent to optimize a loss function that is differentiable
in θ and φ.
Setting the loss function of the neural network to the negative ELBO
l = −Eq[log(pφ(x|z))] +DKL(qθ(z|x)‖pφ(z)),
we see that the first term is equivalent to the cross-entropy reconstruction loss, and the sec-
ond term, the KL-divergence between qθ(z|x) and the prior pφ(z) can be seen as a regular-
ization term, which will push the z’s to their prior distribution.
Stacking autoencoders
The Variational Autoencoder described above is for a one-layer bayesian framework,
i.e. Figure 3.2a. But Autoencoders may be stacked (Bengio et al., 2007) to produce deeper
neural network architectures. Deep architectures have more than one layer of nonlinear-
ities, and can thus more compactly capture highly nonlinear functions. We introduce a
hidden layer to our Bayesian latent variable model (Figure 3.2c).
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(a) Plate model of latent
factor model; x ∼ p(x|z).
(b) Visual representation of Variational Autoencoder.
(c) Plate model of stacked
latent factor model.
(d) Visual representation of Stacked Variational Autoen-
coder.
Figure 3.2: Graphical models and neural net-
work schematics of corresponding Autoen-
coders. a, b: latent variable model. c, d: mul-
tilevel latent variable model. This figure is
reproduced from Ronen et al. (2018).
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Using the reparametrization trick as above, and specifying the full loss function, infer-
ence in the generative model (Figure 3.2c can be done by backpropagation in the stacked
variational autoencoder model (Figure 3.2d).
Model regularization
Deep neural networks have many parameters, making them very flexible. This
flexibility, however, comes at a cost—deep models are prone to over-fitting: the generation
of models which explain the training data well, but generalize poorly to new data. In addi-
tion, deep nets are prone to producing complex relationships between many variables. In
the case of a latent variable model, that means latent factors that change with the variation
of any of a large number of input features, a property which makes the task of interpret-
ing the biological meaning of those latent factors difficult. In technical terms, we wish to
enforce sparsity in qθ(z|x), so that each latent factor will depend on fewer of the inputs.
In order to address the first issue of potential over-fitting, I use Batch Normalization
(Ioffe and Szegedy, 2015). When fitting the model, we segment the data into mini-batches,
at each iteration computing derivatives and making updates to the model based on that
sample. Using Batch Normalization, each feature is scaled and centered in each mini-batch.
We feed all of the training examples to the model fitting procedure until the entire training
set is exhausted, and then we segment it into newminibatches and repeat the process, for a
specified number of epochs. This way, each time a training sample is passed to the model,
it will be slightly different, which is roughly equivalent to adding noise, which has been
shown to work as a regularizer in Denoising Autoencoders (Vincent et al., 2010) and pre-
vent over-fitting. Further, Batch Normalization addresses another issue - that of Internal
Covariate Shift. Internal Covariate Shift happens when the distributions of activations of
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internal nodes in the neural network changes while training. Reducing Internal Covariate
Shift enables us to pick higher learning rates, and thus speeds up inference considerably.
The second mode of regularization, encouraging representations where latent factors
depend only on a few input features, is partially achieved by the KL term in the loss func-
tion, as that penalizes distributions of z’s which are far from the Gaussian prior. Disentan-
gled representations, where latent factors depend on complementary input feature sets,
can support this kind of sparsity. This holds when latent factor representations are non-
negative, which we achieve by passing them through a rectifier unit (ReLU). When each
non-negative latent factor depends on a different set of inputs, the relationships will be
sparser.
We therefore add a multiplier to the loss function similar to β-VAEHiggins et al. (2017)
and , allowing us to weigh the relative importance of the terms:
l = −Eq[log(pφ(x|z))] + βDKL(qθ(z|x)‖pφ(z))
In order to ensure the network finds a good representation before it starts regularizing,
we use the ”warm-up” method proposed by Sønderby et al. (2016), where β is initially 0,
and is gradually increased by β = β + κ until its value reaches 1.
Model implementation
The model was implemented using Keras (v2.1.5) with a Tensorflow (v1.6.0) backend.
I used Rectified Linear Units for all activations except for the last layer which is Sigmoids,
for all features. I trained our network for 600 epochs using mini-batches of size 100 and
κ = .01. I used the Adam optimizer (Kingma and Ba, 2014).
78
Predicting CMS from latent factors using SVM
In order to quantify the correspondance between latent factors learned by dif-
ferent methods, adn the CMS label, I used Support Vector Machines (Hastie et al., 2001)
(SVM), a supervised learning algorithm. I used a regularized SVM, picking the optimal reg-
ularization parameter using 10-fold cross-validation (CV). Then, I predict the CMS label of
each sample out-of-sample, when it is in the test set, using 10-fold CV. Receiver operating
characteristic (ROC) curves were computed for each class by modeling a binary outcome
for each CMS label (one-vs-all). Mean ROC curves were computed by averaging the ROC
of all CMS labels at each point.
Unsupervised prediction of CMS using k-means clustering
I benchmarked maui against MOFA and iCluster+ in the power of latent factors to pre-
dict CMS labels in an unsupervised fashion, in order to present a fair comparison between
maui (70 latent factors) andMOFA (20 latent factors) and iCluster+ (10 latent factors). I
used k-means clustering, as clustering based on distance metrics suffers from the ”curse of
dimensionality”, and does not, in general, benefit from a larger number of input dimen-
sions (unlike supervised learning methods). To assess the ability of k-means clusters to cap-
ture the CMS labels, I ran k-means with 1,000 starts, picking the best (lowest variance) so-
lution for each run. In addition, I applied the algorithm withK’s in the range of 2–9. For
the cluster assignments for eachK , I computed the AdjustedMutual Information (AMI)
of the clustering with the CMS labels. The AMI is an information-theoretic measure of
the concordance between two labelings (clusterings and CMS), which accounts for chance.
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Higher values indicate closer relationships between labelings.
A novel subtyping scheme for CRC with cell line associations to subtypes
The subtyping scheme presented in the results section is based on k-means
clustering usingmaui latent factors learned frommulti-omics data. I did this using amaui
model trained on 6,000 input features (5,000 gene expression, 500 mutation, 500 CNV),
as it is more predictive of patient survival than the one using 1,300 features (Figure 3.3F),
and produces largely the same cluster assignments as the 1,300 gene model presented above
(Figure B.12).
Association of latent factors with genomic features
The Stacked Variational Autoencoder model described above computes latent
factors z = f(x)where f(x) is a nonlinear function which may not necessarily be well-
approximated by a linear z ≈ Wx, as in models such as MOFA or iCluster+. The ar-
chitecture and depth of the neural network also makes it nontrivial to associate the input
genomic features (gene expression, mutations, etc.) with the different latent factors. How-
ever, in order to make biological sense of the latent factors, it is necessary to make that asso-
ciation. In order to do that, I computed Spearman’s ρ for each latent factor with each input
feature, and call a latent factor associated with an input feature if p < 0.001.
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Gene set enrichment
In order to identify genes associatedwith the different clusters, I per-
formed a differential expression analysis using t-tests and Benjamini-Hochberg correction
for multiple hypothesis testing. Genes with adjusted p value below 0.05 were called dif-
ferentially expressed. In order to find out if the genes associated with latent factors (Fig-
ure 3.5), or with clusters (Figure 3.4) belong to known pathways, I used Enrichr (Chen
et al., 2013; Kuleshov et al., 2016) via the python package gseapy *. I used pathways (gene
sets) defined by KEGG (Kanehisa, 2000; Kanehisa et al., 2015, 2016).
Survival analysis
I rely on overall survival data from the TCGA annotations for all survival analyses.
In order to assess the prognostic value of latent factors inferred by our deep learning ap-
proach, I fit a Cox Proportional Hazards model (Breslow, 1975),
ln
h(t)
ho(t)
=
∑
i
βixi,
where the left hand side is the logarithm of the hazard ratio, and x’s are co-variates. I assess
the predictive value of each latent factor separately, while controlling for the patient’s age,
gender, and tumor stage at diagnosis. I compute confidence intervals for the coefficient
β associated with the latent factor, and pick the latent factors with FDR-correction and
α = 0.95.
*version 0.9.4, available from PyPI https://pypi.org/project/gseapy
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In order to compare the prognostic value of different models, we compute Harrel’s C
index (Harrell et al., 1982, 1984, 1996) and use 5-fold cross-validation (Hastie et al., 2001).
The log-rank statistics reported in Figure 3.3D and Figure B.3 are multivariate log-rank
test, under a null hypothesis that all groups have the same survival function, with an alter-
native hypothesis that at least one group has a different survival function.
All survival analysis was done using the python package lifelines *.
Comparing models’ survival-predictive value
In order to compare maui to MOFA and iCluster+ (as well as to a gene expression
only-basedmauimodel), I used Harrell’s C in a Cox Proportional Hazards regression model (Bres-
low, 1975; Pencina and D’Agostino, 2004). The c-Index was computed for Cox models
based only on clinically relevant factors, which I select using individual, unregularized Cox
models, one per factor, while controlling for patient age, sex, and tumor stage. Using unreg-
ularized models ensures this first feature selection is done in an unbiased fashion. In those
individual factor models, I used Efron’s method to compmute confidence intervals, and
only kep the latent factors with statistically significant (adjusted P-value< 0.05) nonzero
coefficients in the individual Cox models. Having selected clinically relevant latent factors
from each model (maui, MOFA, iCluster+,maui—expression,maui—netSmooth), we fit a
full Cox regression using those, and ran a cross validated out-of-sample c-Index calculation
using regularized Cox PH regression, searching for the optimal result among the regular-
izers 1, 10, 100, 1000, 10000. The results reported in Figure 3.3F are the best regularized
model for each of the methods.
*https://lifelines.readthedocs.io/en/latest/
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Model selection
The stacked VAE presented above is a class of models which are parameterized by the
number of hidden units (the dimensionality of h),Nhidden, and the number of latent fac-
tors,Nlatent.
This presents an opportunity for selecting the best model by spanning a grid over the
two parameters, and computing some score. We searched the space spanned by (Nhidden, Nlatent)
and computed a compound benchmark score at each point. The compound benchmark
score is the average of the scores of: the AUC in the supervised CMS prediction task, the
AMI in the unsupervised CMS subtype prediction task, the−log10p of the multivariate
log-rank test for differential survival statistics, and the c-index Pencina and D’Agostino
(2004) from the Cox proportional hazards model. Maui is largely insensitive to the choice
of (Nhidden, Nlatent), forNlatent > 30 (Figure B.10).
MOFA was run using the default parameters. It uses heuristics in order to pick the num-
ber of latent variables, starting with a large number and pruning away ones with explained
variance ratio of beneath a threshold of 2%. The resulting model had 20 components. In
order to see if MOFA’s heuristic picks a sensible model, we also ran it with fixed numbers
of latent factors over a range from 10 to 30, and computed the composite benchmark, lower
than for maui due to the higher runtime.
For iCluster+, there are two free parameters: the regularization parameter λ, and the
number of latent factors. We ran a grid search over the regularization parameter and num-
ber of latent variables space, similar to the way maui was tuned, but with a lower number
of maximum latent factors, due to iCluster+’s prohibitive runtime for larger numbers. For
each parameter configuration, we computed the compound benchmark. maui consistently
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outperforms bothMOFA and iCluster+ for most parameter sets (Figure B.11).
For the final analyses shown in the results section, in order to avoid leakage of bench-
marks into the unsupervised learning algorithms, we ran maui and with parameters corre-
sponding the the mean of the distribution of compound benchmarks (Nhidden = 1100 and
Nlatent = 100); the same reasoning for iCluster+ resulted in 5 latent factors. We allowed
MOFA to use its own heuristic, discarding latent factors with variance explained below 2%,
yielding a 20 component model. We used the MOFA default threshold when picking the
number of components to keep in the PCA comparison, which yielded 5 components.
Quality assessment of CRC cell lines for modeling tumors
In order to assess the fitness of different cancer cell lines as models for tu-
mors, I computed the pairwise euclidean distance between each of the samples (TCGA and
CCLE), in the space of the latent factors derived frommaui. Then, I computed, for each
cell line, the proportion of its 5 nearest neighbors which are also cell lines, the working hy-
pothesis being that cell lines that form ”cell line clusters” are more cell-line like than tumor
like, and likely less fit as models for tumors. I repeated the exercise considering other num-
bers of nearest neighbors from 1—20, at eachK computing the true positive rate (recall),
that is, # non-colon cell lines predicted to be poor models
# of non-colon cell lines
, showing that the recall is near perfect for a wide
range ofK’s.
3.3 Results
In the pages that follow, I will usemaui to find a latent factor representation of
CRC tumors and cancer cell lines frommulti-omics data. I will use this latent factor rep-
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resentation to define sub-types of the disease, refining the CMS classification scheme. I will
demonstrate that these sub-types are bioligically distinct, and carry clinical implications. I
will show thatmaui performs better than state-of-the-art methods for multi-omics integra-
tion. Finally, I will demonstrate howmaui can be used for quality control of cancer models,
and to assign them to cancer sub-types.
Refining CRC subtypes using multi-omics data
The CRC cohort in the TCGA data-set (n=519, See Materials andMethods) has been
extensively studied, and a state-of-the-art subtyping scheme exists in the ”Consensus Molec-
ular Subtypes” for colorectal cancer, or CMS (Guinney et al., 2015) (Table 3.1). In order to
validate that the latent factors learned bymaui capture patterns relevant to cancer biology, I
tested how well the latent factors recapitulate the known subtypes.
I extracted latent factors from gene expression, point mutations, and copy number al-
terations usingmaui, as well as other published methods for multi-omics integration by
dimensionality reduction: MOFA (Argelaguet et al., 2018), and iCluster+ (Mo et al., 2013).
In order to quantify the relationship between latent factor representations and the CMS
subtype to compare the methods, I used Support Vector Machines (SVM, See Methods) to
assign a CMS label to each tumor based on their latent factor representation. I then com-
puted Receiver operating characteristics (ROC), and computed the area under the curve
(see Methods). The area under the ROC (auROC) is a measure of classification accuracy,
with a score of 0.5 being expected from random guessing, and 1.0 being perfect. All meth-
ods produce latent factors with some correlation to the CMS labels (Figure 3.3A). Using
SVM,maui (auROC 0.98) marginally outperformsMOFA (auROC 0.96) and bothmaui
andMOFA dramatically out-perform iCluster+ (auROC 0.73) (Figure 3.3B, Figure B.2).
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maui has an unfair advantage over MOFA in the previous analysis, as I ran it with 80
latent factors, whereas MOFA was only run with 20, and regularized supervised learning
algorithms may benefit from a larger number of input features (here, the latent factors). In
order to assess which of the methods is best able to capture the CMS labels, without regard
to the number of latent factors, I repeated the previous exercise—predicting the CMS from
the latent factors—using an unsupervised learning algorithm. I clustered the samples with
a well-defined CMS * using k-means clustering on the latent factors (See Methods). I letK
vary from 2—9, and for eachK , computed the AdjustedMutual Information (AMI) of the
clustering with the CMS labels. k-means clustering only reproduces the CMS subtype to a
significant degree forK values of 4—6, and only usingmaui (Figure 3.3C). This clustering
analysis shows thatmaui factors are superior at predicting CMS labels, in a fair compari-
son, as k-means clustering is based on distances, whose computation does not benefit from
higher dimensionality — in fact, the opposite is true (Trunk, 1979).
Latent factors inferred bymaui are predictive, using k-means, of the CMS subtype, es-
pecially usingK’s 4—6 (Figure 3.3C). In order to pick the best clustering result to focus on,
I computed the log-rank statistic for significance of differential survival rates between clus-
ters (See Methods). K = 6 results in the most statistically significant survival difference
(P < 0.001, Figure 3.3D). Note that the CMS subtypes on their own are not indicative of
survival rates in the TCGA data (P = 0.77), and that maui withK = 4 (P < 0.045) and
K = 5 (P < 0.019), also produce clusters with significant differential survival (Figure B.3).
Notably,K = 6 is preferable toK = 4 andK = 5, as it is able to tease out a cluster with
particularly poor prognosis (cluster 3), which consists mostly of a subset of tumors with
the CMS2 (Canonical) designation (Figure B.3). K-means clustering of MOFA or iClus-
ter+ latent factors does not produce statistically significantly separable clusters (Figure B.4,
*Some CRC samples do not have a consensus molecular subtype
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Figure B.5).
I also compared the ability ofmaui, MOFA, and iCluster+ to predict patient survival,
irrespective of any clustering. I first selected, for each model, a subset of latent factors which
are individually predictive of patient survival, and call those clinically relevant latent fac-
tors (See Methods). Using those clinically relevant latent factors, I fit a Cox Proportional
Hazards regression, and computed Harrell’s c-Index (Pencina and D’Agostino, 2004) (See
Methods). The c-Index is a measure of prediction accuracy for censored data, with a score
of 0.5 being expected by random guessing, and a score of 1.0 being perfect. maui (c=0.72)
outperforms bothMOFA (c=0.68) and iCluster+ (c=0.64) in this benchmark (Figure 3.3E).
The CMS subtyping scheme, as well as much of the work in the field, is based solely
on gene expression profiles. In order to examine whethermaui gives better predictions
of patient survival with the addition of mutations and copy number data, I also trained a
mauimodel based on gene expression alone. Themauimodel based on expression alone
(c=0.69) achieves a lower score than amauimodel with multi-omics data (c=0.72), even
when the former is given more genes as input features (Figure 3.3F), indicating that data
other than transcriptomes do contribute to overallmaui performance. One of the advan-
tages ofmaui over other methods such as iCluster+ andMOFA is that it is able to learn
orders of magnitude more latent factors, at a fraction of the computation time (Table 3.2).
In order to demonstrate the advantage of being able to fit larger models, I also trained a
mauimodel based on 6,000 multi-omics features (see Methods), and that model (c=0.75)
outperforms the smaller model (Figure 3.3F), demonstrating the clinical utility of learning
frommore input genes.
Finally, I investigated the applicability of using prior information from protein interac-
tion networks for colorectal cancer subtyping. I and others previously incorporated gene-
gene interactions using a method called network-smoothing (see chapter 2 on page 33).
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Network-smoothing is done by allowing binary mutation values to diffuse over a gene
network, a process which assigns non-zero ”mutation scores” rather than binary muta-
tion values, to genes which either have mutations, or interact with mutated genes. I used a
gene network defining interactions between genes from the STRING-db (Szklarczyk et al.,
2016) database of protein-protein interactions. I applied the netSmooth (Ronen and Akalin,
2018a) algorithm (see Methods) to the mutation data prior to passing it tomaui and com-
puted Harrell’s c-Index, as above. Network smoothing mutations further improves the
clinical relevance of latent factors learned when integrating multi-omics data (c=0.79), (Fig-
ure 3.3G).
A closer examination of the clusters reveals how closely themaui clusters resemble the
CMS subtypes, and where they diverge. CMS1 is captured by cluster 2, CMS2 is split be-
tween clusters 3 and 5, CMS3 is captured by cluster 0, CMS4 overlaps with cluster 4, and
cluster 1 is mixed (Figures 3.4A-C). A similar conclusion can be reached based on a set of
molecular indicators introduced in (Guinney et al., 2015): CMS1 and cluster 2 show the hy-
permutated (Figure B.6A), CIMP (Figure B.6B), and microsatellite unstable phenotypes
(Figure B.6C). They also have similar mutation rates among TP53, APC, KRAS and BRAF
(Figure B.6D), a set of commonly mutated genes in colorectal cancers.
Figures 3.4C and B.6 beg the question of why CMS2 was split into two clusters (3 and
5). In order to investigate whether it is biologically plausible that the CMS group needs to
be split into two, I performed a differential expression analysis, identifying marker genes
for each cluster. I then ran these lists through a gene set enrichment analysis (See Meth-
ods). The top pathways associated with eachmaui cluster are associated with a distinct
set of pathways (Figure 3.4D). Specifically, cluster 3 is dominated by TGF-β signaling and
leukocyte migration, while cluster 5 is dysregulated in the ErbB, Hippo, andWnt signal-
ing pathways, demonstrating that these are indeed distinct groups with different molecular
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Figure 3.3: maui, MOFA, iCluster+, and the CMS labels. A) UMAP (McInnes and Healy, 2018) reduced dimensions
from latent factors inferred by maui, MOFA, and iCluster+. Each dot represents a tumor, colored by their CMS la-
bel. B) ROC’s for regularized SVM’s predicting the CMS label from latent factors (out-of-sample, 10-fold CV). Mean
ROC shown (See Methods) C) The Adjusted Mutual Information (AMI, See Methods) of clusters obtained from latent
factors inferred by maui, MOFA, and iCluster+, using k-means clustering with K ranging from 2 to 9. D) Kaplan-
Meier estimates and the log-rank statistic for differential survival of different clusters. The reported P value is from
a multivariate log-rank test, under a null hypothesis that all groups have the same survival function. Clusters 3 and
5 represent a novel splitting of a previously defined subtype, CMS2. E) Harrell’s c-Index for Cox regressions of iClus-
ter+, MOFA, and maui shows maui is more predictive of patient survival than other methods. F) Harrell’s c-Index
comparing different maui flavors shows that maui benefits from multi-omics data, as well as from more input genes.
G) Harrell’s c-Index shows network smoothing of mutations improves survival prediction using maui. This figure is
reproduced from Ronen et al. (2018).
phenotypes. Further demonstrating this, cluster 3 presents a worse prognosis than cluster 5
(log-rank P < 0.001, Figure B.7). Another cluster, cluster 4 (CMS4) is enriched in path-
ways associated with mobility and structural differences (Figure 3.4D), which is consistent
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with CMS4 displaying more stromal infiltration (Guinney et al., 2015).
Figure 3.4: Clustering the tumors using k-means using the latent factors from maui reproduces the CMS labels
closely, with the exception of CMS2 being split into two clusters, 3 and 5. A) UMAP embedding of tumors colored
by CMS label, B) UMAP embedding colored by k-means clusters on maui latent factors, C) Cluster diagram shows
the correspondence between maui clusters and the CMS subtypes: the two rows represent the different labeling
schemes (maui clusters and CMS subtypes), and each column represents a sample, which is colored according with
its assignment in each row. The legend in subfigures A-B applies to the color scheme in C as well. D) Pathways that
are enriched in differentially expressed genes for each maui cluster. Clusters show a disjoint set of dysregulated path-
ways, underlining the different molecular phenotypes which underlie each group. Cluster 3 and 5 (which together
make up the bulk of CMS2) are dominated by dysregulation of TGF-β signaling, and ErbB/Wnt/Hippo signaling,
respectively. This figure is reproduced from Ronen et al. (2018).
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Method Notes # Factors Runtime
iCluster+ Bayesian, MCMC 10 ∼11hrs
MOFA Bayesian, varia-
tional
20 20mins
maui Multilevel
Bayesian, Stochas-
tic Gradient
Descent
100 3 mins
Table 3.2: Summary of methods. This table is reproduced from Ronen et al. (2018).
CRC latent factors are associated with processes related to tumour progression
and development
Thanks to its superior computational efficiency,maui is able to infer many
latent factors frommulti-omics data. This creates an opportunity to select the most inter-
esting latent factors and treat them as potential biomarkers. In order to demonstrate this, I
fit Cox Proportional Hazards models (Breslow, 1975), fitting one regression model for each
factor, as above, selecting clinically relevant latent factors (See Methods). Figure 3.5B shows
the 95% confidence interval of coefficients for these latent factors, showing that high values
for some of these latent factors are predictive of a poor prognosis (β > 0), while others are
predictive of more favorable outcomes (β < 0). In general, these latent factors can be used
as biomarkers with a significant prognostic value.
Beyond the potential to use these latent factors values as biomarkers in order to prognos-
ticate, it is important that I be able to interpret what these biomarkers represent. maui is
very powerful because it can learn highly non-linear patterns. This comes at a certain cost:
the biological interpretation of the factors is less straightforward than in a linear matrix
factorization approach, like PCA orMOFA. PCA andMOFA learn linear relationships be-
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tween genes and latent factors, of the form x = Wz, whereW is directly available, and
in it the connections between latent factors and genes. maui does not produce a straight-
forward, linearW , and so, in order to associate latent factors with input genes, I correlated
input genes with latent factor values (see Methods). While most latent factors are active
in the gene expression domain, most are not significantly affected by mutation data, while
others capture interactions between two or more omics types (Figure 3.5A). By correlating
latent factors with input features in this way, we can overcome the difficulties presented by
the nonlinear relationships between factors and input features, and use the associations in
order to find biologically relevant interpretations for neural latent factors.
When I associated clinically relevant (See Methods) latent factors with gene ids, I ob-
served enrichment of pathways known to play a role in CRC such as Wnt signaling and
other APCmediated processes (Figure 3.5C). In addition, one of the the most significantly
survival associated factors is enriched in Neuronal growth factor (NGF) signaling associated
genes. NGF signaling, which controls neurogenesis, is associated with aggressive colorectal
tumours (Jobling et al., 2015; Liebig et al., 2009). Survival-relevant latent factors also impli-
cate Platelet-Derived Growth Factor (PDGF) signaling which is also associated with stromal
invasion and poor prognosis for colorectal cancer patients (Kitadai et al., 2006; Steller et al.,
2013). Thus, in addition to using latent factors as potential biomarkers for prognosis, we
can also point at the underlying biological processes that are uncovered bymaui, poten-
tially driving future drug-target studies.
Quality assessment of CRC cell lines as models for tumors
The molecular profiles of cancer cell lines often differ significantly from those of tu-
mors, due to the differences in selective pressures faced by cells in culture and natural tu-
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Figure 3.5: Interpretation of maui latent factors. A) A heatmap showing the absolute correlation coefficients of the
different input genes with the latent factors. Only input features with significant correlations (Padj < 0.01, see
Methods) are shown in the heatmap. The row annotation shows the type of input feature, i.e. expression value, mu-
tation, or copy number. B) The coefficients in a Cox Proportional Hazards regression for factors which are clinically
relevant (*) when controlling for patient age, sex, and tumor stage. Coefficients also shown for those covariates. C)
Pathway enrichment scores for genes associated with the latent factors which carry prognostic value (have significant
effects in Cox regression). (*) Clinically relevant factors are factors with a coefficient in a fitted Cox model controlling
for age, sex, and tumor stage, which are statistically significantly nonzero (Padj < 0.05). This figure is reproduced
from Ronen et al. (2018).
mor microenvironments; adaptation requires distinct genomic alterations Ben-David et al.
(2018). This means that not all colorectal-derived cancer cell lines are likely to have equal
value as models for tumors. Furthermore, over time cancer cell lines run the risk of con-
tamination and mis-labeling. For instance, a cell line which was originally annotated as
colorectal, has been shown to be derived frommelanomaMedico et al. (2015). Since the
identification and quality control of the cell lines are crucial steps in the research process,
it is essential to know if the lines have diverged too much from tumors in their molecular
makeup, been mis-labeled, or contaminated. We examined 54 cancer cell lines derived from
tumors of the colon from the Cancer Cell Line Encyclopedia (CCLE). We used maui to
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infer latent factor values for the cell lines, to permit their characterization using the same la-
tent factors as the tumors. As cell lines may develop adaptations specific to cell culture, their
molecular profiles are often more similar to other cell lines than to those of primary tumors.
We therefore hypothesized that cancer cell lines that are more similar to other cell lines than
to tumors are less likely to be appropriate models for CRC tumors. We compiled a list of
nearest neighbors (See Methods) for each cell line, and then counted howmany of its near-
est neighbors are cell lines (as opposed to tumors). We used euclidean distance in the space
defined by the latent factors to determine similarity, and found that about half of the col-
orectal cancer cell lines we investigated belong to a ”cell line cluster”, meaning that the ma-
jority of their neighbors were other cell lines (Figure 3.6A). We eliminated cell lines where
this proportion is above half, and found among them a mis-labeled cell line: COLO741,
which has been shown to derive frommelanoma and not colorectal cancer*. This finding
indicates the merit of using this method to flag cell lines as poor models for tumors.
In lieu of knowledge of other mis-labeled or otherwise inappropriate colon-derived can-
cer cell lines, we artificially contaminated the data set by adding a random sample of 60
non-colon cell lines, assuming that these would be ill-suited to the study of colorectal can-
cer tumors†. We used this to repeat the exercise of counting the nearest-neighboring cell
lines. With the introduction of these true positives‡, we found that more of the cell lines
could be assigned to a ”cell line cluster” in which the majority of their neighbors are other
cell lines (Figure 3.6B). For nearly all non-colon derived cell lines, the 5 nearest neighbors
were other cell lines, while this was not the case for colon-derived cell lines (Figure 3.6C). As
a result, we designated cell lines whose 5 nearest neighbors are other cell lines, as less suit-
*In more recent versions of the CCLE annotations, this has been fixed.
†The identities of these ”known contaminant” cell lines are irrelevant, as we show later that the method
works on 100 such random draws.
‡Non-colon cancer cell lines are considered true positives in the task of predicting which cell lines are
poor models for CRC tumors.
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able for the study of colorectal tumors (”rejected”), as they more closely resemble other
cell lines, even those derived from other tissues. We retain cell lines with at least one tu-
mor among their 5 nearest neighbors as more likely to be suitable models. The choice of
K = 5 for the number of nearest neighbors is immaterial, as the method is insensitive
to the choice ofK (Figure B.8). UMAP embedding of the latent factor space of tumors
(with CMS labels, n=419), colorectal cancer cell lines (n=54), and non-colorectal (artificial
contamination, n=60) cancer cell lines shows that this procedure eliminates most contam-
ination cell lines, as well as some of the colon cancer cell lines, and that non-rejected cell
lines are spread among all clusters (Figure 3.6D). We repeated the analysis with 100 more
random draws of 60 additional contaminants. For each such draw, we rejected any cell line
whose 5 nearest neighbors are cell lines. This method consistently rejects almost all known
contaminants, as well as about half of the colorectal cancer cell lines (Figure 3.6E). Reject-
ing these cell lines is not necessarily a mistake because even if they originate in colon cancer,
this does not guarantee they will be good genomic models for a such tumors, due to e.g. ge-
nomic divergence, mis-labeling, or contamination. Additionally, the fact that a particular
cell line more closely resembles non-colon-derived cancer cell lines than CRC tumors is an
indication that it might not be suitable as a model for colorectal cancers. That this method
successfully rejects almost all known contaminants is another indication that rejected colon
cancer cell lines are likely to be poor models for CRC as well. The colorectal cancer cell lines
CL40, SW1417, and CW2 are deemed most suitable as models for CRC tumors (Figure 3.7).
Using the same criteria, the cell line COLO320 ranked among the lowest. COLO320 lacks
mutations in major CRC driver genes such as BRAF, KRAS, PIK3CA and PTEN, and it is
actually of a neuroendocrine origin Ahmed et al. (2013); Berg et al. (2017). This very likely
makes COLO320 a poor model for CRC.
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Figure 3.6: For each cell line, we compiled a list of 5 nearest neighbors in latent factor space, and counted the propor-
tion of those nearest neighbors who are cell lines (as opposed to tumors). Cell lines whose 5 nearest neighbors are
all other cell lines, are marked as less likely to be appropriate models for tumors, as they are more similar to cell lines
than to tumors. A) histogram of the proportion of nearest neighbors of cell lines which are also cell lines, colorectal
cancers only, B), histogram of the proportion of nearest neighbors of cell lines which are also cell lines, colorectal
cancers and non-colorectal cell lines C) KDEs of the proportion of cell-line neighbors among all cell lines (colorectal
and non-colorectal), broken down by tissue, D) UMAP embedding of tumors and cell lines. Crosses are colon-derived
cell lines, diamonds are artificial contamination (non-colon derived cancer cell lines). Red cell lines are rejected, black
ones are retained as more likely to be good models. E) The proportions of colon and non-colon cell lines which are
rejected because their proportion of nearest-neighbor-cell-lines is above the threshold. Nearly all non-colon cell lines
are consistently rejected, as well as about half of the colon cell lines.
A complete subtyping scheme for CRC and appropriate cell lines for the study
of each subtype
The ConsensusMolecular Subtyping (CMS) scheme (Guinney et al., 2015) is in-
complete as it leaves many tumors without a CMS label. I usedmaui to assign subtypes to
the remaining non-CMS tumors by repeating the clustering analysis, and including also tu-
mors that don’t have a CMS designation, as well as cancer cell lines. By also including the
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Figure 3.7: For all colon-derived cell lines, we compiled lists of their 5 nearest neighbors. The barplot shows how
many of those 5 were other cell lines. Cell lines where all 5 nearest neighbors are other cell lines are rejected, those
having at least one nearest neighbor who is a tumor are kept and assigned to clusters, as shown in the table on the
right.
cancer cell lines which were deemed to be suitable models (see above), I also assigned CRC
subtypes to the cancer cell lines. Here, I present a novel subtyping scheme for CRC, which
covers the whole TCGA cohort (including tumors without a CMS designation), as well as
an association of CRC cell lines with these subtypes. The non-CMS samples are distributed
roughly according to cluster size, as is to be expected for samples that lack a consensus def-
inition (Figure 3.8A-B), and all clusters have at least one associated cell line (Figure 3.8C,
Table 3.3). The cluster with the most associated cell lines is cluster 2 (CMS1, MSI), which
consists of hyper-mutated tumors with low chromosomal instability, and indeed the cell
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lines that I matched with cluster 2 show the same characteristics (Figure B.9), again indicat-
ing that latent factors capture patterns which are important to cancer biology. I hope that
this can be a useful resource for future drug discovery studies in colorectal cancers.
Figure 3.8: A) The sizes (number of samples) of the clusters, B) The number of non-CMS tumors assigned to each
cluster, C) the number of cancer cell lines associated with each cluster D) Cluster diagram shows the correspondence
between maui clusters and the CMS subtypes: the two rows represent the different labeling schemes (maui clusters
and CMS subtypes), and each column represents a sample, which is colored according with its assignment in each
row. The NOLBL samples without a defined CMS subtype are distributed among all clusters, as are cancer cell lines
(CCLE). This figure is reproduced from Ronen et al. (2018).
3.4 Discussion
Colorectal cancer (CRC) is a heterogeneous disease, with different subtypes
being driven by different kinds of genomic alterations, e.g. hypermutated tumors, tumors
showing chromosomal instability, etc. Multi-omics data analysis has the potential to in-
crease the understanding of different subtypes of the disease, and newmethods which scale
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Cluster Description Cell lines
0 CMS3 (metabolic) SW948, CL14, SNU1197, RCM1, NCIH508,
CL40, T84, SKCO1
1 Mixed type SNU283, MDST8
2 CMS1 (msi, immune) CW2, HT115, SNU1040, HCT15, SW48,
HCT116, RKO, SNUC2A
3 CMS2-TGF-beta SW480
4 CMS4 (mesenchymal) OUMS23, SNU503, NCIH716
5 CMS2-ErbB-Hippo-Wnt SW403, LS1034, SW620, SW1417
Table 3.3: maui clusters and the cancer cell lines associated with them. This table is reproduced from Ronen et al.
(2018).
computationally are necessary as the amount of available data increases. Apart from strati-
fying patients into clinically relevant subgroups, it is necessary to find potential drug targets
specific to each subtype. Most drug target discovery studies use cancer models such as cell
lines, organoids, or xenografts, and it is thus necessary to match these cancer models to the
appropriate subtype in each study, or if a cancer model is inappropriate for the study of any
subtype, to be able to flag it as such.
I have developed an autoencoder-based method, calledmaui, for integrating data from
multi-omics experiments, and demonstrated it using RNA-seq, SNPs and CNVs. maui
infers latent factors which explain the variation across the different data modalities. The
latent factors inferred bymaui capture important biology such as different gene expres-
sion programs, mutational profiles, copy number profiles, and their interactions. I showed
that, usingmaui to learn latent factors in multi-omics data, we get latent factors which are
predictive of previously described CRC subtypes (the Consensus Molecular Subtypes,
CMS).maui outperforms the other methods I benchmarked it against, namely iCluster+
andMOFA.maui also outperformsMOFA and iCluster+ in survival prediction regard-
less of the CMS subtypes. From the standpoint of computational performance,maui can
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extract more latent factors from larger datasets, at a fraction of the computational cost of
both iCluster+ andMOFA, makingmaui better suited to the analysis of the larger datasets
we expect to see more of in the future. I have shown thatmaui is able to leverage its com-
putational efficiency to learn from larger data sets, containing more genes, to produce latent
factors which are more predictive of patient survival. These latent factors also produced
a novel classification for CRC.While this novel classification reproduced the CMS nearly
perfectly, it revealed that one of the CMS subtypes, CMS2, is in fact two distinct tumor
subtypes, with different survival characteristics, and different underlying gene expression
programs. These results show that an unbiased selection of more input genes, rather than
restriction to knownmarkers or driver mutations, increases prognostic value. Our results
support the idea that passenger mutations as well as driver mutations could have an effect
on cancer prognosis (McFarland et al., 2017).
iCluster+, which we compared to maui in the first part of this study, is already strained
at 1,300 input genes (runtime of 11 hours), and in the future, with even more data types
(e.g. methylation), we expect the input spaces to grow far beyond the 6,000 that were used
here*. Hence, the computational efficiency of maui is not a mere academic exercise; at to-
day’s scale, this increase in computational efficiency is the difference between a model that
can be fit at all and one which cannot. In addition to using more input features, the com-
putational efficiency allows maui to learn more latent factors than we might believe to truly
exist in the data. This is desirable in latent factor models, as fitting more latent factors in-
creases the amount of ground-truth factors which are recovered by a method. This effect
tends to outweigh any harm that may come from overparameterizing the model Buhai et al.
(2019). By e.g. ranking latent factors by their clinical relevance (as in Figure 3.5B), we have
*We still recommend that users of maui who are interested in using e.g. DNAmethylation data perform
some feature selection on the 450k or so CpG’s, in a similar way to the feature selection we performed on gene
expression, mutation, and copy number data.
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shown that we can fish out the ground truth latent factors from a potentially overparam-
eterized model. So here too, the computational efficiency premium offered by maui over
iCluster+ andMOFA comes with real-world benefits.
The latent factors can also be individually associated with genes, as well as by their indi-
vidual relevance to survival prediction. When I performed a pathway analysis on the latent
factors which are most predictive of patient survival, I observed enrichment of pathways
which are known to play a role in CRC, such as WNT signaling and other APC-mediated
processes, NGF signaling, and PDGF signaling (Kuipers et al., 2015). While the association
of latent factors to individual genes is not as straightforward usingmaui as it is using ma-
trix factorization methods, the relevance of the implicated pathways is promising. I also
proposed a way to use the latent factors learned bymaui to predict the fitness of cancer cell
lines as models for CRC generally, as well as for specific subtypes. In order to address the
first question, I hypothesized that cell lines which are poor models for the study of CRC
tumors will show higher similarity to other cell lines than to CRC tumors. By including
non-colorectal cancer cell lines in the sample and checking if a cell line is more similar to
other cell lines than to CRC tumors, we correctly predict that 98% of non-colorectal cancer
cell lines are poor models for CRC. The method also predicts that approximately 45% of the
colorectal cell lines are poor models for CRC, a prediction which still needs to be validated
by new experiments, although the method reliably rejected previously known inappropri-
ate cell lines such as COLO741 and COLO320 (Medico et al., 2015; Ahmed et al., 2013; Berg
et al., 2017). The rejected cell lines may still be used to study genetic interactions etc., but
their utility in studies of e.g. adaptive drug response may be limited. On the other hand,
SW480 and SW620 cell lines that are predicted to be a good match for CRC show similar
drug response to clinical trials on KRASmutant tumours (Sun et al., 2014).
By including the predicted appropriate cell lines in the clustering analysis, I assigned
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CRC subtype-specific cell lines, a finding with far reaching potential for subtype specific
drug trials. One of the clusters (cluster 2, CMS1) consists mainly of hyper-mutated tumors
with low CIN, and the cell lines I matched with that cluster usingmaui, share those same
characteristics; matching such characteristics has been a standard way to find disease-specific
cell lines (Cheng et al., 2018), and this shows thatmaui cell line matches also preserve this
desired behavior. I hope in the future it can be tested whether our approach to predicting
fitness of cancer cell lines as models for tumors can be verified, and extended to other cancer
models, such as organoids and xenografts. In that way,maui could become an indispensable
part of drug discovery pipelines and speed up new therapeutics.
The CRC subtypes I used as a starting point for this study were defined based on gene
expression profiles alone. As I wanted to use multi-omics data to refine these subtype def-
initions, I was limited to a subset of the tumors used in the CMS definition. I used only
samples from the TCGAwhich had measurements for both gene expression, mutations,
and copy numbers (n=519), while the CMS study used a larger cohort (n=4,151) and only
gene expression profiles. Consequently, it is unclear whether the splitting of the CMS2 sub-
type into two clusters which I have proposed above would hold when presented with a
larger dataset. Only once a larger multi-omics dataset is available will this question be an-
swered.
While the autoencoder architecture ofmaui is able to do inference in larger data at a frac-
tion of the time compared with matrix factorization methods such as MOFA and iClus-
ter+, the resulting model is more challenging to interpret biologically, i.e. linking genes
with latent factors is not as straightforward as in matrix factorization. I have proposed to
solve this by using correlations of the input genes and the latent factors, picking the most
significant ones heuristically. While I was able to show that such latent factor—gene rela-
tionships capture meaningful cancer biology and recapitulate known associations between
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dysregulation of certain pathways and patient survival, this method is potentially less ro-
bust than matrix factorization to these associations, and might require more user involve-
ment in the analysis pipeline.
In this study I have developed a deep learning based multi-omics integration method
(maui) and shown that it can be used to define clinically relevant subtypes of CRC, as well
as predict the fitness of cancer cell lines as models for the study of tumors, and an associa-
tion of cell lines to CRC subtypes. The latent factors inferred bymaui are also interpretable
in biological context, and predictive of patient survival, which enables the associations be-
tween underlying oncogenic processes, and patient survival. I benchmarkedmaui against
two state-of-the-art methods for multi-omics data integration, and showed that not only
is it more effective in defining clinically meaningful subtypes, it also does so with superior
computational efficiency. Being orders of magnitude faster will enablemaui to be used in
studies with larger cohorts and more omics types, as these experiments become more abun-
dant in the future. Further,maui is a general tool for multi-omics integrations, and may
be used outside of the cancer context as well, in basic biology studies employing multiple
genomic assays.
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4
Discussion
This doctoral work has resulted in a book chapter about multi-omics data integra-
tion in the R programming language, as well as two articles describing original methods for
integrative data analysis, one for single cell RNA sequencing data imputation, and another
using deep learning to integrate multi-omics data in a joint latent factor model. The meth-
ods presented in those publications (and this dissertation) make a contribution to the wide
field of computational methods integrating data from different experiments, a field which
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is likely to continue growing as experimental protocols for same-sample multi-omics prolif-
erate and the cost of sequencing continues to plummet. The tools have been released to the
scientific community under free, open source software licenses, and packaged versions have
been made available through standard channels (Bioconductor and the Python Package
Index, PyPI), where they have received thousands of downloads*†.
4.1 Network diffusion to integrate data from past experiments
Single cell RNA sequencing has provided transcriptome profiling at a resolution and
throughput which were not possible before, but is often associated with the cost of reduced
quality measurements. This reduced quality manifests itself in higher technical variance,
which leads to the so-called drop-out phenomenon, where genes which are expressed in a
cell are perceived as not being expressed, due to e.g. loss of RNAmaterial while handling
such minute quantities (Pierson and Yau, 2015). Drop-outs, i.e. false zero’s, have been dealt
with in the literature by imputation methods which essentially guess the true expression
value of a gene by looking at its expression values in other cells which are similar, e.g. (van
Dijk et al., 2017; Lin et al., 2017; Li and Li, 2017).
In chapter 2 I described netSmooth, a quasi imputation method I developed based on
an orthogonal approach: network diffusion on a gene-gene network. Rather than guess a
gene’s true expression level based on its expression in other similar cells, my method guesses
its expression level based on the expression levels of other genes which are known to be
co-expressed. I demonstrated this using a protein-protein interaction network, which is
reasonably predictive of co-expression (Bhardwaj and Lu, 2005; Fraser et al., 2004). Using
*http://bioconductor.org/packages/stats/bioc/netSmooth/
†https://pepy.tech/project/maui-tools
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netSmooth, down-stream analysis tasks such as clustering, are improved in biological sys-
tems including embryonic development, hematopoiesis, and cancer.
This is an interesting result also because the gene network I used in all three cases was
the same— a global protein-protein interaction network of the most confident gene inter-
actions in the STRINGdb database (Szklarczyk et al., 2017). Global in this context means
the network represents gene all gene interactions, without filtering for a specific context
(e.g. gene interactions which are known to be important in hematopoiesis or other biolog-
ical systems). However, we know that gene interactions can be cell type specific. Interac-
tions between miRNAs and their target mRNAs follow cell type specific patterns, (Sood
et al., 2006), as do protein-protein interactions (Gora et al., 2010). It is a testament to the
true signal-recovering abilities of netSmooth that it works with global (not context specific)
gene networks. Future efforts to infer context specific gene regulatory networks, miRNA–
mRNA interactions, and protein-protein interactions, will surely result in an even more
effective netSmooth.
Recently, it has been suggested that the drop-out phenomenon, i.e. that genes that are
expected to be expressed are not detected in scRNA-seq, is not a technical issue, but rather
an expected result of the biological variability in gene’s transcription rates (Svensson, 2019).
It is interesting to observe that the direct imupation methods scImpute, MAGIC, etc. re-
duce this drop-out phenomenon much more than does netSmooth (Figure A.7 on page 119).
A consequence of this aggressive imputation is that after applying MAGIC or scImpute,
many more gene pairs are significantly correlated than what is reasonable to expect (Fig-
ure 2.2 on page 50, Figure A.5 on page 117, Figure A.8 on page 120). In fact, in many cases,
MAGIC and scImpute processing leads to gene pairs being highly correlated even when
they are never observed in the same cell! (Erik van Nimwegen called this ”hallucinating
correlations” (Unpublished)). Hence, netSmooth’s approach of inferring expression values
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based on expected co-expression rather than forced imputation under strong assumptions,
is more appropriate for recovering the true signal in scRNA-seq experiments.
These properties make netSmooth, the R package I developed implementing this algo-
rithm, a versatile tool for denoising any genomic data for which a high quality gene net-
work may be constructed, in a global or context-specific manner, extending its usability
beyond single cell RNA sequencing analysis.
4.2 Using deep learning to integrate multi-omics data
Advances in the mechanistic understanding of tumerogenesis have lead to a re-
finement of the X-cancer label (where X is some tissue) into more informative sub-diseases.
A high-profile example is the sub-typing of breast cancers based on the presence of hor-
mone receptors (reviewed in Althuis et al. (2004)). Targeted therapies developed for the
different sub-types (e.g. Herceptin), have lead to a remarkable improvement of both mor-
tality rates and quality of life (due to a reduced used of systemic cytotoxic chemotherapy)
(MillionWomen Study Collaborators et al., 2003). Large consortia such as TCGA have
profiled thousands of tumors, including thousands of breast cancer tumors, using different
omics platforms, and revealed molecular signatures for the different sub-types which span
different omics types (Ciriello et al., 2015). This underlines the need for multi-omics analysis
strategies for cancer genomics.
Chapter 3 describesmaui (Ronen et al., 2018) (Multi-omics AUtoencoder Integration),
a method I developed, and demonstrates the superiority of the multi-omics-first approach
in sub-typing colorectal cancers. maui uses state-of-the-art advances in gradient descent
(Kingma and Ba, 2014), together with a novel neural network architecture, in order to learn
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latent factor representations of multi-omics data with superior computational performance
over similar methods. maui can integrate multi-omics data from gene expression (RNA-
seq), mutations and copy number variations (DNA-seq), in order to learn a latent factor
representation for colorectal cancer. Using the latent factor representation produced by
maui, I was also able to refine the state-of-the-art subtyping system, the Consensus Molec-
ular Subtype (CMS, Guinney et al. (2015)), by splitting one subtype, CMS2, into two sep-
arate subgroups with distinct molecular signatures and survival probabilities. The CMS2
should be split into two distinct sub-groups of colorectal cancer, one defined by ErbB,
WNT, and Hippo dysregulation, and the other by TGF-β activation. Incidentally, the lat-
ter (TGF-β) subtype includes some of the most aggresive tumors in the TCGA cohort,
with median survival of< 1 year. The other CMS2 subset (defined by ErbB, WNT, and
Hippo signalling activation) makes up some of the least aggressive tumors in the cohort,
with median survival of> 6 years (Figures 3.4, 3.3D ). Using maui, I was able to answer a
question which has been raised by many oncologists in recent times, in fact, each time I pre-
sented this work in progress to clinicians — does adding multi-omics data to gene expres-
sion actually improve the clinical results? And can whole-genome assays be mined for more
clinically relevant information than targeted screens? I was able to answer both questions in
the affirmative (Figure 3.3F,G on page 89).
Nearly all of the targeted therapies developed for different cancers rely on cancer mod-
els, e.g. cancer cell lines, at some stage in the drug discovery pipeline. A major challenge for
drug discovery trial designers is choosing appropriate cell lines to model distinct diseases.
Typically, a pharmaceutical company will start by identifying a group of patients which is
sufficiently large and lack satisfactory treatment options, to initiate a drug discovery trial.
Then, in an initial phase, cancer cell lines which are thought to be good models for the sub-
group of interest may be screened for the effects of known compounds, or using genetic
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engineering, for critical genes, the silencing of which kills the cell line. Consequently, the
identification of appropriate cell lines is a lively field for developments for pharmaceutical
companies. I usedmaui to map colon cancer cell lines to the latent factor space defined by
colorectal cancer tumors, and assigned each cancer cell line to a subtype, a resource which
can help drug discovery trials (Table 3.3). Using this method, I was also able to rank the
cancer cell lines by their suitability as models for colorectal cancers, using a novel method-
ology. The method correctly flagged COLO741 and COLO320 as unsuitable models; these
cell lines are known to be inappropriate models for colorectal tumors (Medico et al., 2015;
Ahmed et al., 2013; Berg et al., 2017). I also produced a complete ranking of all colorectal
cancer cell lines from the CCLE (Figure 3.7).
I benchmarkedmaui against other methods for learning latent factors frommulti-omics
data, iCluster+ andMOFA, andmaui outperforms them on the clinical relevance of the
latent space it uncovers, and is also orders of magnitude more computationally efficient,
which allows learning of factors frommany more input features (genes), using many more
samples, and at a fraction of the computational cost. Thus,maui is well suited for multi-
omics integration studies, both in the realm of cancer and in other realms, and I believe
maui or methods like it will become indispensible parts of many research pipelines in the
future.
4.3 Combining netSmooth and maui
In chapter 3, I showed that using netSmooth in tandem withmaui further improves can-
cer subtyping, generating latent representations of the data with superior clinical relevance
(Figure 3.3 on page 89G). This demonstrates the power of computational methods incorpo-
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rating priors from the countless experiments which have been made public over the recent
decades. As sequencing experiments produce data with high variability, due to both tech-
nical and biological reasons, incorporating data from other relevant experiments is a great
way to improve analytic results by removing undesired noise and improving pattern recog-
nition.
4.4 Final remarks
Multi-modal artificial neural networks (ANNs) likemaui have recently been
used for protein function prediction by integrating different protein interaction networks
(Gligorijević et al., 2018), and for small molecule synthesis (Winter et al., 2019). Also outside
the world of computational biology, multi-modal deep learning models have flourished.
As a vivid and highly accessible example*, by training an autoencoder-like network using
images and text data, with each image being associated with a textual description (caption),
such models have been made to generate plausible image captions for previously unseen im-
ages (Kiros et al., 2014; Vinyals et al., 2016). With an even stronger hold over our collective
cultural imagination of ”thinking machines”, multi-modal ANNs are behind many recent
advances towards autonomous vehicles, where data modalities include (visible light) video,
radar, LIDAR, etc. (Chen et al., 2015). More practically, similar models have made break-
throughs in machine translation, by treating text in different languages as multi-modal data
(Kalchbrenner and Blunsom, 2013; Cho et al., 2014; Bahdanau et al., 2014; Sutskever et al.,
2014); this tool is used by hundreds of millions of people worldwide daily (Wu et al., 2016;
Shankland, Shankland). Taken together, these advances, using similar technology in dif-
ferent fields, represent nothing short of a new paradigm of knowledge discovery and rep-
*https://github.com/tensorflow/models/tree/master/research/im2txt
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resentation. Another exciting trend in this field, which is best embodied by convolutional
neural networks (CNNs) used for image processing, is bio-mimicking of neural networks.
CNNs are directly biologically inspired, with convolution followed by pooling layers used
in CNNs resembling the LGN–V1–V2–V4–IT structure of the ventral pathway in the vi-
sual cortex of a cat (Hubel andWiesel, 1962; Felleman and Van, 1991; LeCun et al., 2015).
Perhaps in the future we will find analoguous biologically inspired models for neural multi-
modal integration, a task the brain of even much simpler organisms surely performs. Per-
haps we will be able to uncover more of biology’s greatest tricks for knowledge discovery
and representation, and point them directly at biology itself.
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A
Supplementary material for Chapter 2
Choice of dimensionality reduction for clustering procedure
netSmooth picks PCA or t-SNE algorithmically, using the 2D entropy in an embedding
of a dataset (see section 2.2). For the hematopoiesis and glioblastoma datasets, this is t-SNE,
while for the embryonic development dataset it is PCA (Table A.1). This method may be
used to pick any dimensionality reduction technique other than the ones mentioned here,
which might be more suitable for other analyses.
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Figure A.1: boxplots of cluster purity for clusters obtained by the robust clustering procedure following application of
netSmooth with different values of α. α = 0 is equivalent to not using netSmooth at all. The procedure is robust to
alpha, that is, most values of alpha produce more robust clusters. A) HSPCs, B) embryonic cells, C) glioblastomas. This
figure is reproduced from Ronen and Akalin (2018a).
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Figure A.2: the proportion of cells in robust clusters, and cluster purity for those robust clusters, for a range of alpha
values, shows that picking the alpha with the highest proportion in robust clusters also picks the alpha with the
highest cluster purity. A) hematopoietic stem/progenitor cells B) embryonic cells, C) glioblastomas. This figure is
reproduced from Ronen and Akalin (2018a).
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Figure A.3: PCA plots of the HSPC dataset A) no preprocessing, B) after application of netSmooth, C), using scImpute,
and D) after application of MAGIC. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.4: t-SNE plots of the HSPC dataset A) no preprocessing, B) after application of netSmooth, C), using scIm-
pute, and D) after application of MAGIC. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.5: single cells from the embryonic development dataset were clustered using the robust clustering proce-
dure, and the log-transformed expression values of the 500 most differentially expressed genes (by edgeR-QLF test
adjusted P value) in any of the discovered clusters are shown in a heatmap, as well as cluster assignments and cell
types. A) raw (no imputation), B) after application of netSmooth, C) missing values imputed using scImpute D) after
application of MAGIC. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.6: t-SNE plots of the embvryonic development dataset A) no preprocessing, B) after application of
netSmooth, C), using scImpute, and D) after application of MAGIC. This figure is reproduced from Ronen and Akalin
(2018a).
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Dataset PCA Entropy t-SNE Entropy
Hematopoiesis 4.96 5.03
Embryonic cells 4.09 3.94
Glioblastoma 4.87 5.06
Table A.1: Entropy in 2D lower dimension embeddings. This table is reproduced from Ronen and Akalin (2018a).
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Figure A.7: The proportion of genes with 0 counts is a proxy for technical dropouts. A) no preprocessing, B) after
application of netSmooth, C), using scImpute, and D) after application of MAGIC. This figure is reproduced from
Ronen and Akalin (2018a).
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Figure A.8: single cells from the glioblastoma dataset were clustered using the robust clustering procedure, and the
log-transformed expression values of the 500 most differentially expressed genes (by edgeR-QLF test adjusted P
value) in any of the discovered clusters are shown in a heatmap, as well as cluster assignments and cell types. A) raw
(no imputation), B) after application of netSmooth, C) missing values imputed using scImpute D) after application of
MAGIC. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.9: PCA plots of the glioblastoma dataset A) no preprocessing, B) after application of netSmooth, C), using
scImpute, and D) after application of MAGIC. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.10: Cluter purity by smoothing parameter. A) for the hematopoiesis dataset with a directional (signed)
graph, where inhibitory interactions have a negative edge weight. B) For the hematopoiesis dataset using a gene
network with only genes that have a cell-type specific expression in any cell type. C) In the glioblastoma dataset
using a gene network from HumanNet. This figure is reproduced from Ronen and Akalin (2018a).
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Figure A.11: Cluster purity including CIDR. Same as Figure 2.3, with CIDR included. This figure is reproduced from
Ronen and Akalin (2018a).
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Figure A.12: Adjusted mutual information including CIDR. Same as Figure 2.3, with CIDR included. This figure is
reproduced from Ronen and Akalin (2018a).
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Figure A.13: Cluster purity including CIDR. Same as Figure 2.5, with CIDR included. This figure is reproduced from
Ronen and Akalin (2018a).
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Figure A.14: Adjusted mutual information including CIDR. Same as Figure 2.5, with CIDR included. This figure is
reproduced from Ronen and Akalin (2018a).
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Figure A.15: Cluster purity including CIDR. Same as Figure 2.7, with CIDR included. This figure is reproduced from
Ronen and Akalin (2018a).
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Figure A.16: Adjusted mutual information including CIDR. Same as Figure 2.7, with CIDR included. This figure is
reproduced from Ronen and Akalin (2018a).
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Figure B.1: PCA for multi-omics integrative analysis. A) UMAP embedding of PCA of multi-omics fusion. B) AUC
for prediction accuracy when predicting CMS label from latent factors inferred by maui, MOFA, iCluster+, and PCA.
C) Adjusted Mutual Information (AMI) between clustering based on latent factors of different methods, and the
CMS label, for k-means clustering with a range of Ks. D) c-Index of Cox Proportional Hazards model based on latent
factors from different methods for multi-omics integration. This figure is reproduced from Ronen et al. (2018).
Figure B.2: Receiver Operator Characteristic curves per class (CMS) for maui, MOFA, iCluster+, and PCA. Mean ROC
curve also shown. auROC reported is the area under the mean ROC. This figure is reproduced from Ronen et al.
(2018).
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Figure B.3: Kaplan Meier curves and log-rank tests for differential survival statistics for the CMS subtypes, as well as
maui clusters using k-means with different K’s. The reported P values are from a multivariate log-rank test, under the
null hypothesis that all groups have the same survival function. This figure is reproduced from Ronen et al. (2018).
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Figure B.4: Kaplan Meier curves and log-rank tests for differential survival statistics for the CMS subtypes, as well
as MOFA clusters using k-means with different K’s. The reported P values are from a multivariate log-rank test, un-
der the null hypothesis that all groups have the same survival function. This figure is reproduced from Ronen et al.
(2018).
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Figure B.5: Kaplan Meier curves and log-rank tests for differential survival statistics for the CMS subtypes, as well
as iCluster+ clusters using k-means with different K’s. The reported P values are from a multivariate log-rank test,
under the null hypothesis that all groups have the same survival function. This figure is reproduced from Ronen et al.
(2018).
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Figure B.6: Molecular markers and their distribution in CMS subtypes (left column) and maui clusters (right column).
A)Mutational load, B) CIMP phenotype, C)Microsatellite instability, and D) the prevalence of mutations in a key set
of colorectal cancer genes. This figure is reproduced from Ronen et al. (2018).
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Figure B.7: Kaplan-Meier curves for maui clusters 3 and 5. Cluster 3 appears to be more aggressive tumors with a
worse prognosis (P < 0.001). This figure is reproduced from Ronen et al. (2018).
Figure B.8: We repeated the exercise of Figure 3.6E, that is, adding non-colon cell lines to the mix, and calculating the
proportion of each cell line’s K nearest neighbors, that are also cell lines (as opposed to tumors). Setting the threshold
at 0.95, the method correctly identifies most non-colon cell lines as less likely to be appropriate models for colorectal
tumors. The recall rate is # models predicted to be less fit among non-colon cell lines# non-colon cell lines , and is largely insensitive to the choice of K. This
figure is reproduced from Ronen et al. (2018).
Figure B.9: The CMS1 subtype, which is captured by maui cluster 2, consists of hyper-mutated tumors with low
chromosomal instability, resulting in tumors with a large number of mutations, but low number of copy number
events (Figure B.6). The cell lines that we matched with cluster 2 also show the same characteristics. This figure is
reproduced from Ronen et al. (2018).
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Figure B.10: The composite benchmark score in the space defined byNhidden, the number of hidden units, and
Nlatent, the number of latent factors in a model. The optimal parameters areNhidden = 1500 andNlatent. =
80 This figure is reproduced from Ronen et al. (2018).
Figure B.11: We ran maui, iCluster+, and MOFA with a set of different parameters, performing a grid-search to find
the best configuration. We computed a composite benchmark score (see Model selection and Figure B.10). This box
plot shows the different results achieved by the different methods, demonstrating that maui tends to outperform
iCluster+ and MOFA for a wide range of parameters. This figure is reproduced from Ronen et al. (2018).
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Figure B.12: Correspondence of maui clusters when training using 1,300 genes and 6,000 genes. Each column is
a sample, and they are colored by their cluster assignment. Clusters are mostly the same when using more input
features, with some refinements taking place. This figure is reproduced from Ronen et al. (2018).
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